{"title":"Growth Factors and Cytokines","description":null,"products":[{"product_id":"gf-010","title":"Epidermal Growth Factor (EGF), Human Recombinant","description":"\u003cp style=\"white-space: pre-wrap;\"\u003eHigh-purity, yeast-expressed recombinant human EGF for cell culture and receptor-binding research. Purified by sequential chromatography and reverse-phase HPLC. This polypeptide is equivalent to human EGF1-52 and identical to gamma-urogastrone.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e\u003cstrong\u003eKEY SPECIFICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eCatalog family: GF-010\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eExpression system: Genetically engineered yeast\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003ePurity: Over 97% by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS-PAGE\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eFormulation: Lyophilized powder\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eStorage: Store at +4°C. Reconstitution is best in water or buffer near neutral pH.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eStability: Several months at +4°C. In solution at pH 4-7, stable for 2-3 months at -20°C.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eBiological activity: Mitogenic activity is measured by stimulation of 3H-thymidine incorporation into human foreskin fibroblast cells. Activity has also been determined by receptor-binding assay using A-431 cells.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e\u003cstrong\u003eSIZES AND CATALOG NUMBERS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e100 µg — GF-010-5\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e500 µg — GF-010-8\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e1 mg — GF-010-9\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e\u003cstrong\u003eTECHNICAL REFERENCES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eCohen S. Journal of Biological Chemistry. 1962;237:1555.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eGregory H. Journal of Cell Science, Supplement 3. 1985:11.\u003c\/p\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003eGeorge-Nascimento C, et al. Biochemistry. 1988;27:797-802.\u003c\/p\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-010\"\u003ePublications using Austral Biologicals EGF\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications and protocols report use of EGF supplied by Austral Biologicals:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3389\/fmolb.2026.1830240\" rel=\"noopener\" target=\"_blank\"\u003eA tissue-engineered human psoriatic skin model: targeting inflammation and glucose metabolism dysregulation in psoriasis using microneedle patches\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRuel et al., Front Mol Biosci (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/mps9030073\" rel=\"noopener\" target=\"_blank\"\u003eI-TEP: A Simple and Affordable Method to Measure Permeability in Reconstructed Tissues Combined with DAMO-TSC-Based Urea Assay\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSahuc et al., Methods Protoc (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jdsc.2025-1048\" rel=\"noopener\" target=\"_blank\"\u003eSafety aspects of using iodoform as a methane-mitigating feed additive to dairy cows: impacts of milk and serum on bovine mammary and human intestinal epithelial cell lines\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRonn et al., JDS Communications (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s13287-025-04478-0\" rel=\"noopener\" target=\"_blank\"\u003eAirway epithelial stem cell renewal and differentiation: overcoming challenging steps towards clinical-grade tissue engineering\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAdamo et al., Stem Cell Res Ther (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms26051825\" rel=\"noopener\" target=\"_blank\"\u003eCorrection of Significant Urethral Anomalies Using a Tissue-Engineered Human Urethral Substitute: Proof of Concept\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCaneparo et al., Int J Mol Sci (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cells14201643\" rel=\"noopener\" target=\"_blank\"\u003eCulture Strategy Determines the Differentiation Status of Sweat Gland Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDe Koninck et al., Cells (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms26041704\" rel=\"noopener\" target=\"_blank\"\u003eEffect of Fibroblast Growth Factor-2 on Melanocyte Proliferation in Tissue-Engineered Skin Substitutes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFerland et al., Int J Mol Sci (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3389\/fbioe.2025.1713156\" rel=\"noopener\" target=\"_blank\"\u003eIsolation and characterization of epithelial cells and fibroblasts from the human penile urethra\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBrownell et al., Front Bioeng Biotechnol (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.2500632122\" rel=\"noopener\" target=\"_blank\"\u003eNeuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDelanne-Cuménal et al., Proceedings of the National Academy of Sciences of the United States of America (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms25115639\" rel=\"noopener\" target=\"_blank\"\u003eAntiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRuel et al., Int J Mol Sci (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms25031513\" rel=\"noopener\" target=\"_blank\"\u003eCancer Spheroids Embedded in Tissue-Engineered Skin Substitutes: A New Method to Study Tumorigenicity In Vivo\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBarbier et al., Int J Mol Sci (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1167\/iovs.65.4.38\" rel=\"noopener\" target=\"_blank\"\u003eExpression and Impact of Fibronectin, Tenascin-C, Osteopontin, and Type XIV Collagen in Fuchs Endothelial Corneal Dystrophy\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTchatchouang et al., Invest Ophthalmol Vis Sci (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms251810227\" rel=\"noopener\" target=\"_blank\"\u003eInfluence of Intraocular Pressure on the Expression and Activity of Sodium-Potassium Pumps in the Corneal Endothelium\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAnney et al., Int J Mol Sci (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1165\/rcmb.2024-0089OC\" rel=\"noopener\" target=\"_blank\"\u003eMicroRNA-155-5p differentially regulates IL-13Ralpha1 and IL-13Ralpha2 expression and signaling driving abnormal lung epithelial cell phenotype in severe asthma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKlein et al., American Journal of Respiratory Cell and Molecular Biology (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/microorganisms12112155\" rel=\"noopener\" target=\"_blank\"\u003eMimicking Urinary Tract Infections Caused by Uropathogenic Escherichia coli Using a Human Three-Dimensional Tissue Engineering Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePellerin et al., Microorganisms (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s00403-024-03131-9\" rel=\"noopener\" target=\"_blank\"\u003ePotential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLee et al., Arch Dermatol Res (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms25031412\" rel=\"noopener\" target=\"_blank\"\u003eThymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePatel et al., Int J Mol Sci (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms24031821\" rel=\"noopener\" target=\"_blank\"\u003eA Newly Developed Chemically Defined Serum-Free Medium Suitable for Human Primary Keratinocyte Culture and Tissue Engineering Applications\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGhio et al., Int J Mol Sci (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-023-46590-2\" rel=\"noopener\" target=\"_blank\"\u003eAn effective method for culturing functional human corneal endothelial cells using a xenogeneic free culture medium\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAlonso-Alonso et al., Sci Rep (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms241914712\" rel=\"noopener\" target=\"_blank\"\u003eComparison of Two Human Skin Cell Isolation Protocols and Their Influence on Keratinocyte and Fibroblast Culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSierra-Sánchez et al., Int J Mol Sci (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/jnc.15982\" rel=\"noopener\" target=\"_blank\"\u003eHeterozygous NF1 dermal fibroblasts modulate exosomal content to promote angiogenesis in a tissue-engineered skin model of neurofibromatosis type-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRoy et al., Journal of Neurochemistry (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/burnst\/tkad043\" rel=\"noopener\" target=\"_blank\"\u003eIn vitro comparison of human plasma-based and self-assembled tissue-engineered skin substitutes: two different manufacturing processes for the treatment of deep and difficult to heal injuries\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSierra-Sánchez et al., Burns Trauma (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/bit.28359\" rel=\"noopener\" target=\"_blank\"\u003eIn vitro glycation of a tissue-engineered wound healing model to mimic diabetic ulcers\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLemarchand et al., Biotechnology and Bioengineering (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jaci.2023.01.022\" rel=\"noopener\" target=\"_blank\"\u003eSARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRosichini et al., J Allergy Clin Immunol (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-023-44868-z\" rel=\"noopener\" target=\"_blank\"\u003eThe combination of cigarette smoke and solar rays causes effects similar to skin aging in a bilayer skin model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGrenier et al., Sci Rep (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cells11091513\" rel=\"noopener\" target=\"_blank\"\u003eAlpha-Linolenic Acid Modulates T Cell Incorporation in a 3D Tissue-Engineered Psoriatic Skin Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMorin et al., Cells (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/pharmaceutics14061129\" rel=\"noopener\" target=\"_blank\"\u003eAntipsoriatic Potential of Quebecol and Its Derivatives\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBouchard et al., Pharmaceutics (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cancers14164011\" rel=\"noopener\" target=\"_blank\"\u003eBisphenols A and S Alter the Bioenergetics and Behaviours of Normal Urothelial and Bladder Cancer Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePellerin et al., Cancers (Basel) (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cancers14153810\" rel=\"noopener\" target=\"_blank\"\u003eCancer-Associated Fibroblasts in a 3D Engineered Tissue Model Induce Tumor-like Matrix Stiffening and EMT Transition\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMillet et al., Cancers (Basel) (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/cpz1.353\" rel=\"noopener\" target=\"_blank\"\u003eEfficient Gamma-Retroviral Transduction of Primary Human Skin Cells Using the EF-c Peptide as a Transduction Enhancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBarbier et al., Current Protocols (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-022-25311-1\" rel=\"noopener\" target=\"_blank\"\u003eEngineered human organ-specific urethra as a functional substitute\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCaneparo et al., Sci Rep (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms231710035\" rel=\"noopener\" target=\"_blank\"\u003eEvaluation of a Serum-Free Medium for Human Epithelial and Stromal Cell Culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCaneparo et al., Int J Mol Sci (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cells11182904\" rel=\"noopener\" target=\"_blank\"\u003eGene Profiling of a 3D Psoriatic Skin Model Enriched in T Cells: Downregulation of PTPRM Promotes Keratinocyte Proliferation through Excessive ERK1\/2 Signaling\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRioux et al., Cells (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms232112859\" rel=\"noopener\" target=\"_blank\"\u003eGlucuronidated Metabolites of Bisphenols A and S Alter the Properties of Normal Urothelial and Bladder Cancer Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePellerin et al., Int J Mol Sci (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9603909\/\" rel=\"noopener\" target=\"_blank\"\u003eIsolation efficiency of collagenase and EDTA for the culture of corneal endothelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSanterre et al., Mol Vis (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/anbr.202200052\" rel=\"noopener\" target=\"_blank\"\u003ePersonalized Scaffolds for Diabetic Foot Ulcer Healing Using Extracellular Matrix from Induced Pluripotent Stem-Reprogrammed Patient Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSantarella et al., Adv Nanobiomed Res (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1080\/21688370.2021.1968763\" rel=\"noopener\" target=\"_blank\"\u003eProtease-activated receptor-2 activation enhances epithelial wound healing via epidermal growth factor receptor\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBandara et al., Tissue Barriers (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1167\/iovs.63.11.3\" rel=\"noopener\" target=\"_blank\"\u003eTGF-β-Mediated Modulation of Cell-Cell Interactions in Postconfluent Maturing Corneal Endothelial Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSanterre et al., Invest Ophthalmol Vis Sci (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms23105507\" rel=\"noopener\" target=\"_blank\"\u003eTie-Over Bolster Pressure Dressing Improves Outcomes of Skin Substitutes Xenografts on Athymic Mice\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCartier et al., Int J Mol Sci (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/antiox10091373\" rel=\"noopener\" target=\"_blank\"\u003eAntioxidant, Anti-Inflammatory, and Anti-Aging Potential of a Kalmia angustifolia Extract and Identification of Some Major Compounds\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGrenier et al., Antioxidants (Basel) (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cancers13215461\" rel=\"noopener\" target=\"_blank\"\u003eBisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePellerin et al., Cancers (Basel) (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms221910810\" rel=\"noopener\" target=\"_blank\"\u003eDifferential Marker Expression between Keratinocyte Stem Cells and Their Progeny Generated from a Single Colony\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAli et al., Int J Mol Sci (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e06182\" rel=\"noopener\" target=\"_blank\"\u003ePolyvinyl alcohol increased growth, migration, invasion, and sphere size in the PK-8 pancreatic ductal adenocarcinoma cell line\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGomi et al., Heliyon (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2147\/ccid.s302997\" rel=\"noopener\" target=\"_blank\"\u003eThe Whitening Properties of the Mixture Composed of Pomegranate, Osmanthus and Olive and the Protective Effects Against Ultraviolet Deleterious Effects\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Clin Cosmet Investig Dermatol (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cancers12102976\" rel=\"noopener\" target=\"_blank\"\u003eFGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSasaki et al., Cancers (Basel) (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.msec.2020.111075\" rel=\"noopener\" target=\"_blank\"\u003eReduced graphene oxide membranes in ocular regenerative medicine\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZambrano-Andazol et al., Materials Science and Engineering C (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ma12203325\" rel=\"noopener\" target=\"_blank\"\u003eBiological Assessment of Zn-Based Absorbable Metals for Ureteral Stent Applications\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eParamitha et al., Materials (Basel) (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1096\/fj.201801059\" rel=\"noopener\" target=\"_blank\"\u003eDifferentiation of diabetic foot ulcer-derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKashpur et al., FASEB J (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms21010256\" rel=\"noopener\" target=\"_blank\"\u003eDihydrochalcone Derivatives from Populus balsamifera L. Buds for the Treatment of Psoriasis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBélanger et al., Int J Mol Sci (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/ijfs.14247\" rel=\"noopener\" target=\"_blank\"\u003eEffect of food ingredients on glucagon-like peptide-1 secretion in STC-1 and HuTu-80 cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYue et al., International Journal of Food Science \u0026amp; Technology (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-019-55867-4\" rel=\"noopener\" target=\"_blank\"\u003eGanglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSasaki et al., Sci Rep (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.omtm.2019.05.013\" rel=\"noopener\" target=\"_blank\"\u003eGeneration of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGhani et al., Mol Ther Methods Clin Dev (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.ajoc.2019.100532\" rel=\"noopener\" target=\"_blank\"\u003eGrafting of an autologous tissue-engineered human corneal epithelium to a patient with limbal stem cell deficiency (LSCD)\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLe-Bel et al., Am J Ophthalmol Case Rep (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.celrep.2019.04.055\" rel=\"noopener\" target=\"_blank\"\u003eLaminin 332-Dependent YAP Dysregulation Depletes Epidermal Stem Cells in Junctional Epidermolysis Bullosa\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDe Rosa et al., Cell Reports (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/cells8101142\" rel=\"noopener\" target=\"_blank\"\u003eModulation of the Lipid Profile of Reconstructed Skin Substitutes after Essential Fatty Acid Supplementation Affects Testosterone Permeability\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSimard et al., Cells (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/toxsci\/kfz140\" rel=\"noopener\" target=\"_blank\"\u003eSelective Ah Receptor Ligands Mediate Enhanced SREBP1 Proteolysis to Restrict Lipogenesis in Sebocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMuku et al., Toxicol Sci (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.12.060\" rel=\"noopener\" target=\"_blank\"\u003eTargeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYuan et al., Int J Pharm (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/term.2864\" rel=\"noopener\" target=\"_blank\"\u003eVitrification and storage of oral mucosa epithelial cell sheets\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOliva et al., J Tissue Eng Regen Med (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3791\/56742\" rel=\"noopener\" target=\"_blank\"\u003eAn efficient in vitro transposition method by a transcriptionally regulated Sleeping Beauty system packaged into an integration defective lentiviral vector\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBenati et al., Journal of Visualized Experiments (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms19082174\" rel=\"noopener\" target=\"_blank\"\u003eAre the Effects of the Cholera Toxin and Isoproterenol on Human Keratinocytes' Proliferative Potential Dependent on Whether They Are Co-Cultured with Human or Murine Fibroblast Feeder Layers?\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCortez Ghio et al., Int J Mol Sci (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1369\/0022155418788117\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of Epidermal Lipoxygenase Expression in Normal Human Skin and Tissue-Engineered Skin Substitutes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSimard-Bisson et al., J Histochem Cytochem (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/ten.tea.2017.0128\" rel=\"noopener\" target=\"_blank\"\u003eExtracellular Matrix and Integrin Expression Profiles in Fuchs Endothelial Corneal Dystrophy Cells and Tissue Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGoyer et al., Tissue Eng Part A (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jcyt.2018.02.336\" rel=\"noopener\" target=\"_blank\"\u003eFirst-in-human application of the self-assembled skin substitute as permanent graft to treat burn patients: a case series of 14 patients indicating clinical effectiveness\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGermain et al., Cytotherapy (2018).\u003c\/span\u003e \u003cspan class=\"ab-publication-type\"\u003eConference abstract\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/rej.2017.1931\" rel=\"noopener\" target=\"_blank\"\u003eNatural Substances for Prevention of Skin Photoaging: Screening Systems in the Development of Sunscreen and Rejuvenation Cosmetics\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKostyuk et al., Rejuvenation Res (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.5021\/ad.2018.30.5.581\" rel=\"noopener\" target=\"_blank\"\u003ePlatycodin D May Improve Acne and Prevent Scarring by Downregulating SREBP-1 Expression Via Inhibition of IGF-1R\/PI3K\/Akt Pathway and Modulating Inflammation with an Increase in Collagen\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSuh et al., Ann Dermatol (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/jfb9030053\" rel=\"noopener\" target=\"_blank\"\u003eSpecialized Living Wound Dressing Based on the Self-Assembly Approach of Tissue Engineering\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCantin-Warren et al., J Funct Biomater (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-018-22821-9\" rel=\"noopener\" target=\"_blank\"\u003eTGF-β1 promotes cell barrier function upon maturation of corneal endothelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBeaulieu Leclerc et al., Sci Rep (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms19102923\" rel=\"noopener\" target=\"_blank\"\u003eThe Tissue-Engineered Human Psoriatic Skin Substitute: A Valuable In Vitro Model to Identify Genes with Altered Expression in Lesional Psoriasis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRioux et al., Int J Mol Sci (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-018-31502-6\" rel=\"noopener\" target=\"_blank\"\u003eTissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBourland et al., Sci Rep (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1155\/2017\/2403072\" rel=\"noopener\" target=\"_blank\"\u003eExpression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJacobsen et al., Biomed Res Int (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrep.2016.09.012\" rel=\"noopener\" target=\"_blank\"\u003eA 3D-psoriatic skin model for dermatological testing: The impact of culture conditions\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDuque-Fernandez et al., Biochem Biophys Rep (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/bph.13568\" rel=\"noopener\" target=\"_blank\"\u003eEffect of connexin 43 inhibition by the mimetic peptide Gap27 on corneal wound healing, inflammation and neovascularization\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eElbadawy et al., Br J Pharmacol (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/cell.2015.0087\" rel=\"noopener\" target=\"_blank\"\u003eGeneration of Induced Pluripotent Stem Cells from Diabetic Foot Ulcer Fibroblasts Using a Nonintegrative Sendai Virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGerami-Naini et al., Cell Reprogram (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0167578\" rel=\"noopener\" target=\"_blank\"\u003eHuman Bone Derived Collagen for the Development of an Artificial Corneal Endothelial Graft. In Vivo Results in a Rabbit Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVázquez et al., PLoS One (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/biores.2016.0036\" rel=\"noopener\" target=\"_blank\"\u003eImproved methods to produce tissue-engineered skin substitutes suitable for the permanent closure of full-thickness skin injuries\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLarouche et al., BioResearch Open Access (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1167\/iovs.15-17625\" rel=\"noopener\" target=\"_blank\"\u003eIn Vivo Functionality of a Corneal Endothelium Transplanted by Cell-Injection Therapy in a Feline Model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBostan et al., Invest Ophthalmol Vis Sci (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1155\/2016\/3825645\" rel=\"noopener\" target=\"_blank\"\u003eOrigin of Serum Affects Quality of Engineered Tissues Produced by the Self-Assembly Approach\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChabaud et al., Scientifica (Cairo) (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0135324\" rel=\"noopener\" target=\"_blank\"\u003eAmniotic Membrane Modifies the Genetic Program Induced by TGFß, Stimulating Keratinocyte Proliferation and Migration in Chronic Wounds\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAlcaraz et al., PLoS One (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.5489\/cuaj.2899\" rel=\"noopener\" target=\"_blank\"\u003eDemonstration of the direct impact of ketamine on urothelium using a tissue engineered bladder model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBureau et al., Can Urol Assoc J (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s40478-014-0181-z\" rel=\"noopener\" target=\"_blank\"\u003eEarly detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eParé et al., Acta Neuropathol Commun (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/srep16763\" rel=\"noopener\" target=\"_blank\"\u003eHigh yield extraction of pure spinal motor neurons, astrocytes and microglia from single embryo and adult mouse spinal cord\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBeaudet et al., Sci Rep (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.5489\/cuaj.2953\" rel=\"noopener\" target=\"_blank\"\u003eOptimization of the current self-assembled urinary bladder model: Organ-specific stroma and smooth muscle inclusion\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOrabi et al., Can Urol Assoc J (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jep.2013.10.034\" rel=\"noopener\" target=\"_blank\"\u003ePicea mariana polyphenolic extract inhibits phlogogenic mediators produced by TNF-alpha-activated psoriatic keratinocytes: impact on NF-kappaB pathway\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGarcia-Perez et al., Journal of Ethnopharmacology (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/ten.tea.2013.0535\" rel=\"noopener\" target=\"_blank\"\u003eSensory neurons accelerate skin reepithelialization via substance P in an innervated tissue-engineered wound healing model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBlais et al., Tissue Eng Part A (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.5489\/cuaj.12217\" rel=\"noopener\" target=\"_blank\"\u003eAn endothelialized urothelial cell-seeded tubular graft for urethral replacement\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eImbeault et al., Can Urol Assoc J (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.1214014110\" rel=\"noopener\" target=\"_blank\"\u003eHigh throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK\/TGFβ pathways as fundamental Notch regulators in breast cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIzrailit et al., Proc Natl Acad Sci U S A (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms14034684\" rel=\"noopener\" target=\"_blank\"\u003eIrradiated human dermal fibroblasts are as efficient as mouse fibroblasts as a feeder layer to improve human epidermal cell culture lifespan\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBisson et al., Int J Mol Sci (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23898067\/\" rel=\"noopener\" target=\"_blank\"\u003eKeratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHakelius et al., Anticancer Research (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4236\/scd.2013.31011\" rel=\"noopener\" target=\"_blank\"\u003eOptimization of the porcine adult skin-derived precursor cell isolation protocol\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIribar et al., Stem Cell Discovery (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/1471-5945-13-2\" rel=\"noopener\" target=\"_blank\"\u003eTGFβ signaling regulates lipogenesis in human sebaceous glands cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMcNairn et al., BMC Dermatol (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1155\/2012\/498373\" rel=\"noopener\" target=\"_blank\"\u003eAnti-inflammatory effects of concentrated ethanol extracts of Edelweiss (Leontopodium alpinum Cass.) callus cultures towards human keratinocytes and endothelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDaniela et al., Mediators Inflamm (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/j.1600-0501.2012.02427.x\" rel=\"noopener\" target=\"_blank\"\u003eBi-layered collagen nano-structured membrane prototype (collagen matrix 10826) for oral soft tissue regeneration: an in vitro study\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNocini et al., Clinical Oral Implants Research (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.ajpath.2012.01.020\" rel=\"noopener\" target=\"_blank\"\u003eEnhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIshiwata et al., Am J Pathol (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joms.2011.10.028\" rel=\"noopener\" target=\"_blank\"\u003eUse of autologous skin equivalents with artificial dermal matrix (Integra) in donor site coverage in radial forearm free flaps: preliminary cases\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePena et al., Journal of Oral and Maxillofacial Surgery (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/bjc.2011.396\" rel=\"noopener\" target=\"_blank\"\u003eAnti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIoannou et al., Br J Cancer (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.01703-10\" rel=\"noopener\" target=\"_blank\"\u003eEpstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKung et al., J Virol (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3892\/ijo.2011.945\" rel=\"noopener\" target=\"_blank\"\u003eMorphological and cytoskeletal alterations of nervous system tumor cells with different culturing methods\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMatsuda et al., International Journal of Oncology (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2174\/1874383801004010028\" rel=\"noopener\" target=\"_blank\"\u003eAnalysis of ligand-receptor interaction on the surface of living cells by fluorescence correlation spectroscopy\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMiyagi et al., The Open Spectroscopy Journal (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.oraloncology.2010.07.001\" rel=\"noopener\" target=\"_blank\"\u003eDendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYuan et al., Oral Oncol (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/carcin\/bgq058\" rel=\"noopener\" target=\"_blank\"\u003eEPS8 upregulates FOXM1 expression, enhancing cell growth and motility\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Carcinogenesis (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3727\/096368910X515854\" rel=\"noopener\" target=\"_blank\"\u003eEvaluation of tumorigenic risk of tissue-engineered oral mucosal epithelial cells by using combinational examinations\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eThepot et al., Cell Transplantation (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/978-1-60761-380-0_24\" rel=\"noopener\" target=\"_blank\"\u003eThree-dimensional human tissue models of wounded skin\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eEgles et al., Methods Mol Biol (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4321\/S1130-05582009000200002\" rel=\"noopener\" target=\"_blank\"\u003eCultivo in vitro con colageno y fibroblastos humanos de un equivalente de mucosa oral de espesor total\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGonzalez Mendez et al., Revista Espanola de Cirugia Oral y Maxilofacial (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1021\/jf901503a\" rel=\"noopener\" target=\"_blank\"\u003eDifferential effects of falcarinol and related aliphatic C(17)-polyacetylenes on intestinal cell proliferation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePurup et al., J Agric Food Chem (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.pep.2008.11.005\" rel=\"noopener\" target=\"_blank\"\u003eEscherichia coli expression and refolding of E\/K-coil-tagged EGF generates fully bioactive EGF for diverse applications\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLe et al., Protein Expression and Purification (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jaci.2008.12.006\" rel=\"noopener\" target=\"_blank\"\u003eInnate immune responses of airway epithelium to house dust mite are mediated through beta-glucan-dependent pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNathan et al., J Allergy Clin Immunol (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/978-1-59745-060-7_15\" rel=\"noopener\" target=\"_blank\"\u003eRegeneration of skin and cornea by tissue engineering\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLarouche et al., Methods in Molecular Biology (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/carcin\/bgn252\" rel=\"noopener\" target=\"_blank\"\u003eRole for EPS8 in squamous carcinogenesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Carcinogenesis (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.m109.032185\" rel=\"noopener\" target=\"_blank\"\u003eToward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNishiyama et al., J Biol Chem (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1167\/iovs.07-0904\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of wound reepithelialization using a new human tissue-engineered corneal wound healing model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCarrier et al., Investigative Ophthalmology \u0026amp; Visual Science (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4161\/cbt.7.4.5533\" rel=\"noopener\" target=\"_blank\"\u003eDifferential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJaramillo et al., Cancer Biology \u0026amp; Therapy (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0450\" rel=\"noopener\" target=\"_blank\"\u003eKeratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePaccione et al., Molecular Cancer Therapeutics (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/0471143030.cb1909s41\" rel=\"noopener\" target=\"_blank\"\u003eThree-dimensional tissue models of normal and diseased skin\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCarlson et al., Curr Protoc Cell Biol (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2652016\/\" rel=\"noopener\" target=\"_blank\"\u003eOptimization of culture conditions for porcine corneal endothelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eProulx et al., Mol Vis (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1165\/rcmb.2007-0031OC\" rel=\"noopener\" target=\"_blank\"\u003eTGF-beta suppresses EGF-induced MAPK signaling and proliferation in asthmatic epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSemlali et al., American Journal of Respiratory Cell and Molecular Biology (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16479251\/\" rel=\"noopener\" target=\"_blank\"\u003eAutologous transplantation of rabbit limbal epithelia cultured on fibrin gels for ocular surface reconstruction\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTalbot et al., Molecular Vision (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4398\" rel=\"noopener\" target=\"_blank\"\u003eDown-regulation of CXCL5 inhibits squamous carcinogenesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMiyazaki et al., Cancer Research (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.yexcr.2006.05.008\" rel=\"noopener\" target=\"_blank\"\u003eEffect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJaramillo et al., Experimental Cell Research (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0210-4806(06)73423-4\" rel=\"noopener\" target=\"_blank\"\u003eIn vitro three-dimensional reconstruction of human bladder mucosa\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ede Diego Rodriguez et al., Actas Urologicas Espanolas (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3892\/ijo.29.1.217\" rel=\"noopener\" target=\"_blank\"\u003eInhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKusama et al., International Journal of Oncology (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0076-6879(05)07055-2\" rel=\"noopener\" target=\"_blank\"\u003ePancreatic duct epithelial cell isolation and cultivation in two-dimensional and three-dimensional culture systems\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAgbunag et al., Methods in Enzymology (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03855.x\" rel=\"noopener\" target=\"_blank\"\u003eTissue inhibitor of metalloproteinase-2 (TIMP-2) expression is regulated by multiple neural differentiation signals\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJaworski et al., J Neurochem (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2005.08.131\" rel=\"noopener\" target=\"_blank\"\u003eDynamic changes in nicotinamide pyridine dinucleotide content in normal human epidermal keratinocytes and their effect on retinoic acid biosynthesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePinkas-Sarafova et al., Biochemical and Biophysical Research Communications (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.bjc.6602861\" rel=\"noopener\" target=\"_blank\"\u003eEctodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE\/ADAM17\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZatovicova et al., Br J Cancer (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2133\/dmpk.19.407\" rel=\"noopener\" target=\"_blank\"\u003eEffect of polycyclic aromatic hydrocarbons on generation and efflux of glutathione conjugates in primary cultured alveolar epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNagayoshi et al., Drug Metabolism and Pharmacokinetics (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0210-4806(04)73173-3\" rel=\"noopener\" target=\"_blank\"\u003eExperimental study about viability of autologous free graft in vitro cultivated urinary epithelium\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ede Diego Rodriguez et al., Actas Urologicas Espanolas (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/bcr907\" rel=\"noopener\" target=\"_blank\"\u003eInvestigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLenferink et al., Breast Cancer Res (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14607751\/\" rel=\"noopener\" target=\"_blank\"\u003eThymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eScupoli et al., Haematologica (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1053\/gast.2002.31093\" rel=\"noopener\" target=\"_blank\"\u003e3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKusama et al., Gastroenterology (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/emboj\/21.10.2451\" rel=\"noopener\" target=\"_blank\"\u003eSignaling disrupts mSin3A binding to the Mad1-like Sin3-interacting domain of TIEG2, an Sp1-like repressor\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eEllenrieder et al., EMBO J (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1017\/S0022029901004782\" rel=\"noopener\" target=\"_blank\"\u003eDifferential effects of retinoids on proliferation of bovine mammary epithelial cells in collagen gel culture\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePurup et al., Journal of Dairy Research (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.2001.281.2.C504\" rel=\"noopener\" target=\"_blank\"\u003eEpidermal growth factor regulation of rat NHE2 gene expression\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eXu et al., American Journal of Physiology-Cell Physiology (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1290\/1071-2690(2001)037%3C0676:FHANSC%3E2.0.CO;2\" rel=\"noopener\" target=\"_blank\"\u003eFeline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTannehill-Gregg et al., In Vitro Cellular \u0026amp; Developmental Biology - Animal (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11406567\/\" rel=\"noopener\" target=\"_blank\"\u003eInhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKusama et al., Cancer Research (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0305-4179(00)00113-3\" rel=\"noopener\" target=\"_blank\"\u003ePorcine small intestinal submucosa (SIS): a bioscaffold supporting in vitro primary human epidermal cell differentiation and synthesis of basement membrane proteins\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLindberg et al., Burns (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1523\/jneurosci.21-04-01257.2001\" rel=\"noopener\" target=\"_blank\"\u003eRegulation of neuregulin expression in the injured rat brain and cultured astrocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTokita et al., J Neurosci (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpgi.2000.278.1.G105\" rel=\"noopener\" target=\"_blank\"\u003eBacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eElliott et al., American Journal of Physiology-Gastrointestinal and Liver Physiology (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.141.9.7684\" rel=\"noopener\" target=\"_blank\"\u003eDifferential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSalahifar et al., Endocrinology (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00885.x\" rel=\"noopener\" target=\"_blank\"\u003eKeratinocytes influence the maturation and organization of the elastin network in a skin equivalent\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDuplan-Perrat et al., Journal of Investigative Dermatology (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/iai.66.10.4917-4923.1998\" rel=\"noopener\" target=\"_blank\"\u003eEffects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBuret et al., Infect Immun (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1096-9861(19980511)394:3%3C386::AID-CNE9%3E3.0.CO;2-Y\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-related growth factors stimulate proliferation of retinal progenitors in the goldfish\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBoucher et al., Journal of Comparative Neurology (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1182\/blood.V92.10.3745\" rel=\"noopener\" target=\"_blank\"\u003eThymocyte contact or monoclonal antibody-mediated clustering of alpha3beta1 or alpha6beta4 integrins activate interleukin-6 transcription factors and IL-6 production in human thymic epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRamarli et al., Blood (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0021-9258(18)41604-3\" rel=\"noopener\" target=\"_blank\"\u003eNerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stimulates their growth by a novel autocrine loop\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDi Marco et al., Journal of Biological Chemistry (1993).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp style=\"white-space: pre-wrap;\"\u003e\u003ca rel=\"noopener\" href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-010_EGF_Datasheet.pdf\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52517536203054,"sku":"GF-010-5","price":80.0,"currency_code":"USD","in_stock":true},{"title":"500 µg","offer_id":52517536235822,"sku":"GF-010-8","price":250.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":52517536268590,"sku":"GF-010-9","price":450.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-010-100ug.png?v=1787974773"},{"product_id":"bbp-360","title":"IGF-Binding protein 4 human (RECOMBINANT)","description":"\u003cp\u003eHuman IGF-Binding protein 4 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 24 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 4 is determined by the inhibition activity of both IGF I and II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e2. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BBP-360_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872547630,"sku":"BBP-360-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bbp-360-5ug.png?v=1788008737"},{"product_id":"bbp-370","title":"IGF-Binding protein 5 human (RECOMBINANT)","description":"\u003cp\u003eHuman IGF-Binding protein 5 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 30 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 5 is determined by the inhibition activity of IGF-I and IGF-II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e2. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BBP-370_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872613166,"sku":"BBP-370-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bbp-370-5ug.png?v=1788008744"},{"product_id":"bp-350","title":"IGF-Binding Protein 2, Human Recombinant","description":"\u003cp\u003eHuman IGF-Binding protein 2 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 31 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable at +4°C, however its stability is under investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 2 is under investigation by the inhibition activity of both IGF I and II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Kiefer, M.C., Schmid, C., Waldvogel, M., Sclapfer, I., Futo, E., Maziarz, F.R., Green, K., Barr, P.J. and Zapf, J. (1992) The Journal of Biological Chemistry, Vol 267, No 18, 12692-12699\u003cbr\u003e2. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e3. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-bp-350\"\u003ePublications using BP-350\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publication report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.10.6711\" rel=\"noopener\" target=\"_blank\"\u003eInteractions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLeal et al., J Biol Chem 274(10):6711-6717 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BP-350_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872645934,"sku":"BP-350-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bp-350-5ug.png?v=1788008736"},{"product_id":"bp-360","title":"IGF-Binding protein 4 human (RECOMBINANT)","description":"\u003cp\u003eHuman IGF-Binding protein 4 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 24 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 4 is determined by the inhibition activity of both IGF I and II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1.Kiefer, M.C., Schmid, C., Waldvogel, M., Sclapfer, I., Futo, E., Maziarz, F.R., Green, K., Barr, P.J. and Zapf, J. (1992) The Journal of Biological Chemistry, Vol 267, No 18, 12692-12699\u003cbr\u003e2. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e3. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BP-360_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872711470,"sku":"BP-360-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bp-360-5ug.png?v=1788008721"},{"product_id":"bp-370","title":"IGF-Binding protein 5 human (RECOMBINANT)","description":"\u003cp\u003eHuman IGF-Binding protein 5 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 30 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 5 is determined by the inhibition activity of IGF-I and IGF-II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1.Kiefer, M.C., Schmid, C., Waldvogel, M., Sclapfer, I., Futo, E., Maziarz, F.R., Green, K., Barr, P.J. and Zapf, J. (1992) The Journal of Biological Chemistry, Vol 267, No 18, 12692-12699\u003cbr\u003e2. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e3. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BP-370_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872744238,"sku":"BP-370-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bp-370-5ug.png?v=1788008737"},{"product_id":"bp-380","title":"IGF-Binding Protein 6, Human Recombinant","description":"\u003cp\u003eHuman IGF-Binding protein 6 is produced in genetically engineered yeast, and purified by affinity chromatography and HPLC.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 24 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Binding activity of human IGF-BP 6 is determined by the inhibition activity of both IGF I and II.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1.Kiefer, M.C., Schmid, C., Waldvogel, M., Sclapfer, I., Futo, E., Maziarz, F.R., Green, K., Barr, P.J. and Zapf, J. (1992) The Journal of Biological Chemistry, Vol 267, No 18, 12692-12699\u003cbr\u003e2. Rechler M.M. and Brown A.L. (1992) Growth Regulation, 2, 55.\u003cbr\u003e3. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ., pages 311-415\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-bp-380\"\u003ePublications using BP-380\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publication report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.10.6711\" rel=\"noopener\" target=\"_blank\"\u003eInteractions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLeal et al., J Biol Chem 274(10):6711-6717 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_BP-380_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518872809774,"sku":"BP-380-2","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-bp-380-5ug.png?v=1788008726"},{"product_id":"ci-420","title":"Interleukin-2 (IL-2), Human Recombinant","description":"\u003cp\u003eHuman Interleukin-2 (IL-2) is a lymphokine which biological effects include activation and proliferation of T cells, B cells, and other lymphokine activated killer cells. Human IL-2 is composed of 133 amino acids, including 3 cysteine residues, two of which are involved in a disulfide bond essential for biological activity. Human and murine IL-2 are 62% homologous, and human IL-2 has been found to be active on murine cell lines. Human Interleukin-2 (RECOMBINANT) is produced in genetically engineered Escherichia coli cells, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 15 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +2°C to +8°C\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months as formulated, at +2°C to +8°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The biological activity is determined by a lymphocyte proliferation assay and each vial contains 160,000 IU (International units)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized in the presence of stabilizer (mannitol), low levels of SDS (preventing aggregation), and Sodium Phosphate. It can be reconstituted in water giving a pH between 7.2-7.8. There are no preservatives in this formulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Gillis, S., Ferm, M.M., Ou, W., and Smith, K.A., The Journal of Immunology, (1978) Vol 120, No. 6, June, 2027-2032\u003cbr\u003e2. Mosmann, T., Journal of Immunological Methods, (1983) Vol 65, 55-63\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_CI-420_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518872842542,"sku":"CI-420-3","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ci-420-10ug.png?v=1788008726"},{"product_id":"ci-460","title":"Interleukin-6 (IL-6), Human Recombinant","description":"\u003cp\u003eHuman Interleukin-6 (IL-6) plays a role in the mediation of the inflammatory and immune response initiated by infection or injury. IL-6 acts on B cells by stimulating differentiation and antibody secretion. IL-6 also exhibits growth factor activity for mature thymic or peripheral T cells, and enhances the differentiation of cytotoxic T cells in the presence of IL-2 or IFNt. This glycoprotein is composed of 184 amino acid residues, and has a 42% homology with murine IL-6. Human Interleukin-6 (RECOMBINANT) is produced in genetically engineered Spodoptera frugiperda insect cells (Sf9) infected with recombinant viruses, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 20-21 kDa (glycoprotein)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 85% pure by SDS gel electrophoresis. There is \u0026lt; 1ng\/mg endotoxin.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e 3H-thymidine uptake by B9 murine thymoma cell line that is IL-6 dependent.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Frozen liquid solution (PBS) at 0.50 mg\/mL (50 µL\/vial)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Taga, T., and Kishimoto, T., (1997) Ann. Rev. Immunology, 15, 797-819\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_CI-460_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"25 µg","offer_id":52518872875310,"sku":"CI-460-33","price":250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ci-460-25ug.png?v=1788008722"},{"product_id":"gf-030","title":"Basic Fibroblast Growth Factor (FGF 2), Human Recombinant","description":"\u003cp\u003eHuman Basic Fibroblast Growth Factor is a mitogen that stimulates cell growth for such cells as fibroblasts, endothelial cells, myoblasts, glial cells and smooth muscle cells. Basic FGF is composed of 146 amino acid residues (pro 1 to ser 146), and is 55% homologous with acidic FGF, including two conserved cysteine residues. Human basic FGF is produced by genetically engineered yeast, and purified by heparin-Sepharose affinity chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 17.5 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH, since it is unstable in acidic solutions. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months, lyophilized or in solution, at pH 6-7 and +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The mitogenic activity of human basic FGF is identical to natural bovine basic FGF, as measured by stimulation of 3H-thymidine incorporation into human foreskin fibroblast cells.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Gospodarowicz, D. (1975) J. Biol. Chem. 250, 2515-2520.\u003cbr\u003e2. Folkman, J. and Klagsbrun, M. (1987) Science 235,442-447\u003cbr\u003e3. Fox, J., et al. (1996) Journal of Biological Chemistry 271: 12578-12584.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-030\"\u003ePublications using Austral Biologicals GF-030\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals GF-030:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s44330-026-00072-9\" rel=\"noopener\" target=\"_blank\"\u003eCell-cultured PDMS vascular model to allow placement of implant devices\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOkuno et al., BMC Methods 3:16 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1063\/5.0222866\" rel=\"noopener\" target=\"_blank\"\u003eGeometrically engineered organoid units and their assembly for pre-construction of organ structures\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKadotani et al., APL Bioengineering (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122256\" rel=\"noopener\" target=\"_blank\"\u003eHydrolytic hydrogels tune mesenchymal stem cell persistence and immunomodulation for enhanced diabetic cutaneous wound healing\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMartin et al., Biomaterials (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3389\/fmedt.2023.1149594\" rel=\"noopener\" target=\"_blank\"\u003eMigration of endothelial cells on the surface of anodized Ni-Ti stent strut\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Frontiers in Medical Technology (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121601\" rel=\"noopener\" target=\"_blank\"\u003eHost type 2 immune response to xenogeneic serum components impairs biomaterial-directed osteo-regenerative therapies\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMartin et al., Biomaterials (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3136\/fstr.26.891\" rel=\"noopener\" target=\"_blank\"\u003eAntiangiogenic Activity of Flavonols in Chorioallantoic Membrane (CAM) Assay\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOkamura et al., Food Science and Technology Research 26:891-896 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s42003-020-0881-9\" rel=\"noopener\" target=\"_blank\"\u003eHydrostatic pressure promotes endothelial tube formation through aquaporin 1 and Ras-ERK signaling\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYoshino et al., Communications Biology (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1083\/jcb.201806065\" rel=\"noopener\" target=\"_blank\"\u003eYAP and TAZ limit cytoskeletal and focal adhesion maturation to enable persistent cell motility\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMason et al., Journal of Cell Biology (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2018.05.182\" rel=\"noopener\" target=\"_blank\"\u003eFluid shear stress suppresses ICAM-1-mediated transendothelial migration of leukocytes in coculture model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSakamoto et al., Biochemical and Biophysical Research Communications (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1096\/fj.201700872r\" rel=\"noopener\" target=\"_blank\"\u003eSkeletal cell YAP and TAZ combinatorially promote bone development\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKegelman et al., FASEB Journal (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-017-13477-y\" rel=\"noopener\" target=\"_blank\"\u003eA Novel Technique for Accelerated Culture of Murine Mesenchymal Stem Cells that Allows for Sustained Multipotency\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCaroti et al., Scientific Reports 7:13334 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1155\/2016\/4651265\" rel=\"noopener\" target=\"_blank\"\u003eProliferation-Related Activity in Endothelial Cells Is Enhanced by Micropower Plasma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSuzuki and Yoshino, BioMed Research International (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s12195-015-0385-8\" rel=\"noopener\" target=\"_blank\"\u003eEndothelial Cell Response Under Hydrostatic Pressure Condition Mimicking Pressure Therapy\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYoshino et al., Cellular and Molecular Bioengineering 8:296-303 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3389\/fendo.2013.00183\" rel=\"noopener\" target=\"_blank\"\u003eBasic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the Veterans Affairs Diabetes Trial\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZimering et al., Frontiers in Endocrinology 4:183 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/ncomms2978\" rel=\"noopener\" target=\"_blank\"\u003eHaemodynamically dependent valvulogenesis of zebrafish heart is mediated by flow-dependent expression of miR-21\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBanjo et al., Nature Communications 4:1978 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.073\" rel=\"noopener\" target=\"_blank\"\u003eRole of nesprin-1 in nuclear deformation in endothelial cells under static and uniaxial stretching conditions\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAnno et al., Biochemical and Biophysical Research Communications (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2012.01.083\" rel=\"noopener\" target=\"_blank\"\u003eRole of paxillin in the early phase of orientation of vascular endothelial cells exposed to cyclic stretching\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Biochemical and Biophysical Research Communications (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/ecam\/nep024\" rel=\"noopener\" target=\"_blank\"\u003eBrazilian Propolis Suppresses Angiogenesis by Inducing Apoptosis in Tube-Forming Endothelial Cells through Inactivation of Survival Signal ERK1\/2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKunimasa et al., Evidence-Based Complementary and Alternative Medicine (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2174\/1874120701004010129\" rel=\"noopener\" target=\"_blank\"\u003eCyclic Force Applied to FAs Induces Actin Recruitment Depending on the Dynamic Loading Pattern\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eUeki et al., Open Biomedical Engineering Journal 4:129-134 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2010.06.092\" rel=\"noopener\" target=\"_blank\"\u003eRole of p120-catenin in the morphological changes of endothelial cells exposed to fluid shear stress\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSakamoto et al., Biochemical and Biophysical Research Communications (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2010.04.051\" rel=\"noopener\" target=\"_blank\"\u003eMeasurements of strain on single stress fibers in living endothelial cells induced by fluid shear stress\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eUeki et al., Biochemical and Biophysical Research Communications (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2010.04.002\" rel=\"noopener\" target=\"_blank\"\u003eEffect of spatial gradient in fluid shear stress on morphological changes in endothelial cells in response to flow\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSakamoto et al., Biochemical and Biophysical Research Communications (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.115\" rel=\"noopener\" target=\"_blank\"\u003eDirect measurement of shear strain in adherent vascular endothelial cells exposed to fluid shear stress\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eUeki et al., Biochemical and Biophysical Research Communications (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0014-4827(03)00138-1\" rel=\"noopener\" target=\"_blank\"\u003eEx vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBianchi et al., Experimental Cell Research (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0304-3835(01)00443-8\" rel=\"noopener\" target=\"_blank\"\u003eResveratrol and quercetin inhibit angiogenesis in vitro\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIgura et al., Cancer Letters (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpendo.2000.279.3.E570\" rel=\"noopener\" target=\"_blank\"\u003eTranscriptional regulation of connective tissue growth factor by cortisol in osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePereira et al., American Journal of Physiology-Endocrinology and Metabolism 279:E570-E576 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0301-472X(00)00160-0\" rel=\"noopener\" target=\"_blank\"\u003eProliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBanfi et al., Experimental Hematology (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1677\/joe.0.1650443\" rel=\"noopener\" target=\"_blank\"\u003ePlacental lactogen-I gene activation in differentiating trophoblast cells: extrinsic and intrinsic regulation involving mitogen-activated protein kinase signaling pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePeters et al., Journal of Endocrinology 165:443-456 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.275.18.13677\" rel=\"noopener\" target=\"_blank\"\u003eRas\/MEK\/ERK Up-regulation of the Fibroblast KCa Channel FIK Is a Common Mechanism for Basic Fibroblast Growth Factor and Transforming Growth Factor-β Suppression of Myogenesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePeña et al., Journal of Biological Chemistry 275:13677-13682 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1242\/jcs.113.7.1161\" rel=\"noopener\" target=\"_blank\"\u003eClonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMuraglia et al., Journal of Cell Science 113:1161-1166 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI3459\" rel=\"noopener\" target=\"_blank\"\u003eBone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGazzerro et al., Journal of Clinical Investigation 102:2106-2114 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S8756-3282(98)00009-X\" rel=\"noopener\" target=\"_blank\"\u003eA Nude Mouse Model for Human Bone Formation in Unloaded Conditions\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMuraglia et al., Bone (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1096-9861(19980511)394:3%3C386::AID-CNE9%3E3.0.CO;2-Y\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-related growth factors stimulate proliferation of retinal progenitors in the goldfish\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBoucher and Hitchcock, Journal of Comparative Neurology 394:386-394 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.139.4.5950\" rel=\"noopener\" target=\"_blank\"\u003eMitogen-Activated Protein Kinase Kinase (MEK) Activity Is Required for Inhibition of Skeletal Muscle Differentiation by Insulin-Like Growth Factor 1 or Fibroblast Growth Factor 2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWeyman and Wolfman, Endocrinology 139:1794-1800 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.1998.274.2.C472\" rel=\"noopener\" target=\"_blank\"\u003eEts-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNaito et al., American Journal of Physiology-Cell Physiology 274:C472-C480 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.138.10.5425\" rel=\"noopener\" target=\"_blank\"\u003eFibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMartin et al., Endocrinology 138:4456-4462 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/bjc.1996.496\" rel=\"noopener\" target=\"_blank\"\u003eDifferential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYashiro et al., British Journal of Cancer 74:1096-1103 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1097-4652(199601)166:1%3C188::AID-JCP20%3E3.0.CO;2-A\" rel=\"noopener\" target=\"_blank\"\u003ePro-inflammatory cytokines downregulate platelet derived growth factor-α receptor gene expression in human osteoblastic cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKöse et al., Journal of Cellular Physiology 166:188-197 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-030_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874186030,"sku":"GF-030-3","price":50.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518874218798,"sku":"GF-030-5","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-030-10ug.png?v=1788008668"},{"product_id":"gf-040","title":"Acidic Fibroblast Growth Factor (FGF 1), Human Recombinant","description":"\u003cp\u003eAcidic FGF is a mitogen for cells of mesodermal and neuroectodermal origin, including fibroblasts, endothelial cells, astrocytes, neuroblasts, osteoblasts, and smooth muscle cells. This protein is composed of 140 amino acid residues, and has a 55% homology with basic FGF, including two conserved cysteine residues. Human Acidic FGF is produced by genetically engineered yeast, and purified by heparin-Sepharose affinity chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 15.5 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by HPLC analysis and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C. It is also possible to keep this protein at low pH (2-5) for a few days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Unstable without a carrier protein like gelatin or bovine serum albumin. It is recommended to add some of these proteins, prior to aliquoting, for longer storage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Human acidic FGF is mitogenic for a variety of normal cells in culture including fibroblasts, glial cells, vascular endothelial cells.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 10 mM Tris-HCl, 1.5 M NaCl, pH 7.0 Concentration: 0.50 mg protein\/ml.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Gimenez-Gallego et al., Biochem. Biophys. Res. Comm.(1986) 138:611\u003cbr\u003e2. Thornton et al. (1983), Science 222, 623\u003cbr\u003e3. Gospadorowicz, D. (1987) Methods Enzymol. 147:106\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-040_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874251566,"sku":"GF-040-3","price":75.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518874284334,"sku":"GF-040-4","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-040-10ug.png?v=1788008668"},{"product_id":"gf-050","title":"Insulin-Like Growth Factor I (IGF-I), Human Recombinant","description":"\u003cp\u003eHuman IGF-I is a potent mitogen for mesenchymally-derived cells. It is composed of 70 amino acid residues, and is 62% homologous with human IGF-II. Human IGF-I is produced by genetically engineered yeast, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 7.5 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months, lyophilized or in solution, at pH 6-7 and +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The material is active in a receptor-binding assay using a membrane preparation from placenta.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ. (New York).\u003cbr\u003e2 D'Ercole, A.J. (1987) J. Dev. Physiol. 9:481-495\u003cbr\u003e3. Daughaday, W.H. and Rotwein, P. (1989) Endocr. Rev. 10:68-91\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-050\"\u003ePublications using Austral Biologicals GF-050\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals GF-050:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.athplu.2024.09.001\" rel=\"noopener\" target=\"_blank\"\u003eThe pro-atherogenic enzyme PAPP-A is active in eluates from human carotid and femoral atherosclerotic plaques\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGude et al., Atherosclerosis Plus (2024).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joca.2023.05.004\" rel=\"noopener\" target=\"_blank\"\u003eAge and oxidative stress regulate Nrf2 homeostasis in human articular chondrocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTaylor et al., Osteoarthritis and Cartilage (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joca.2023.04.006\" rel=\"noopener\" target=\"_blank\"\u003eYes-associated protein nuclear translocation promotes anabolic activity in human articular chondrocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCui et al., Osteoarthritis and Cartilage (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4236\/ojas.2022.123031\" rel=\"noopener\" target=\"_blank\"\u003eEvaluation of the Hypothalamic Kisspeptin System during the Attainment of Puberty in Gilts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eClapper et al., Open Journal of Animal Sciences 12:407-427 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4236\/ojas.2021.114040\" rel=\"noopener\" target=\"_blank\"\u003eEvaluation of the Hypothalamic Kisspeptin System throughout the Estrous Cycle in Gilts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eClapper et al., Open Journal of Animal Sciences 11:591-607 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ani10101766\" rel=\"noopener\" target=\"_blank\"\u003eBedding Application to Feedlot Steers: Influence on Growth Performance, Estimated Maintenance Coefficient, Carcass Characteristics, and Circulating Metabolites in Beef Steers\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSmerchek et al., Animals 10:1766 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/tas\/txaa158\" rel=\"noopener\" target=\"_blank\"\u003eEffects of increasing doses of trenbolone acetate and estradiol on finishing phase growth performance, carcass trait responses, and serum metabolites in beef steers following implantation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSmerchek et al., Translational Animal Science (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.ijcem.com\/files\/ijcem0092842.pdf\" rel=\"noopener\" target=\"_blank\"\u003eIGF-1 increases production of extracellular matrix in human endplate chondrocytes via distinct signaling pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZhang et al., International Journal of Clinical and Experimental Medicine 12:8831-8838 (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joca.2018.12.010\" rel=\"noopener\" target=\"_blank\"\u003eArticular chondrocytes isolated from knee and ankle joints of human tissue donors demonstrate similar redox-regulated MAP kinase and Akt signaling\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCollins et al., Osteoarthritis and Cartilage (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.1719278115\" rel=\"noopener\" target=\"_blank\"\u003eThe ZBED6-IGF2 axis has a major effect on growth of skeletal muscle and internal organs in placental mammals\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYounis et al., Proceedings of the National Academy of Sciences 115:E2048-E2057 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joca.2017.05.011\" rel=\"noopener\" target=\"_blank\"\u003eHigh fat-diet and saturated fatty acid palmitate inhibits IGF-1 function in chondrocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNazli et al., Osteoarthritis and Cartilage 25:1516-1521 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jds.2016-11893\" rel=\"noopener\" target=\"_blank\"\u003eEffects of cinnamaldehyde or monensin on performance of weaned Holstein dairy heifers\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChapman et al., Journal of Dairy Science (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jds.2016-11221\" rel=\"noopener\" target=\"_blank\"\u003eGrowth performance of calves fed microbially enhanced soy protein in pelleted starters\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSenevirathne et al., Journal of Dairy Science (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jds.2016-10876\" rel=\"noopener\" target=\"_blank\"\u003eEvaluation of camelina meal as a feedstuff for growing dairy heifers\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLawrence et al., Journal of Dairy Science (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0150453\" rel=\"noopener\" target=\"_blank\"\u003ePotency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJanssen et al., PLOS ONE 11:e0150453 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jds.2015-10197\" rel=\"noopener\" target=\"_blank\"\u003eEffects of feeding rumen-degradable valine on milk production in late-lactating dairy cows\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHultquist and Casper, Journal of Dairy Science (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3168\/jds.2014-9163\" rel=\"noopener\" target=\"_blank\"\u003eFeeding fat from distillers dried grains with solubles to dairy heifers: II. Effects on metabolic profile\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAnderson et al., Journal of Dairy Science (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.joca.2015.01.014\" rel=\"noopener\" target=\"_blank\"\u003eFunction of the Chondrocyte PI-3 Kinase-Akt Signaling Pathway is Stimulus Dependent\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGreene and Loeser, Osteoarthritis and Cartilage (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4236\/ojas.2015.52019\" rel=\"noopener\" target=\"_blank\"\u003eEffects of Short Term Administration of Genistein on Hypothalamic and Anterior Pituitary Hormones in Ovariectomized Gilts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eClapper and Paulson, Open Journal of Animal Sciences 5:163-173 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0102252\" rel=\"noopener\" target=\"_blank\"\u003eIGF-IR signal transduction protein content and its activation by IGF-I in human placentas: relationship with gestational age and birth weight\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIñiguez et al., PLOS ONE 9:e102252 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0063838\" rel=\"noopener\" target=\"_blank\"\u003eDeficiency of insulin-like growth factor-1 receptor confers resistance to oxidative stress in C2C12 myoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eThakur et al., PLOS ONE 8:e63838 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2337\/db12-1773\" rel=\"noopener\" target=\"_blank\"\u003eConcentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVarewijck et al., Diabetes 62:2539-2544 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/ar3705\" rel=\"noopener\" target=\"_blank\"\u003eExtracellular nicotinamide phosphoribosyltransferase (NAMPT\/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYammani et al., Arthritis Research \u0026amp; Therapy 14:R23 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s00125-011-2435-7\" rel=\"noopener\" target=\"_blank\"\u003eAddition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVarewijck et al., Diabetologia 55:1186-1194 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0026891\" rel=\"noopener\" target=\"_blank\"\u003eDoes reduced IGF-1R signaling in Igf1r+\/- mice alter aging?\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBokov et al., PLOS ONE 6:e26891 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpregu.00535.2010\" rel=\"noopener\" target=\"_blank\"\u003eIGF-I\/PI3K\/Akt and IGF-I\/MAPK\/ERK pathways in vivo in skeletal muscle are regulated by nutrition and contribute to somatic growth in the fine flounder\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFuentes et al., American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 300:R1532-R1542 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1097\/HJH.0b013e328335d291\" rel=\"noopener\" target=\"_blank\"\u003eAngiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOcaranza et al., Journal of Hypertension 28:1054-1064 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/cdd.2009.150\" rel=\"noopener\" target=\"_blank\"\u003ePI3K p110α and p110β have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMatheny and Adamo, Cell Death \u0026amp; Differentiation (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.100\" rel=\"noopener\" target=\"_blank\"\u003eEffects of PI3K catalytic subunit and Akt isoform deficiency on mTOR and p70S6K activation in myoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMatheny and Adamo, Biochemical and Biophysical Research Communications 390:252-257 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.M109.056838\" rel=\"noopener\" target=\"_blank\"\u003eOxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-kinase-Akt and MEK-ERK MAPK signaling pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYin et al., Journal of Biological Chemistry (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2009.08.101\" rel=\"noopener\" target=\"_blank\"\u003eRole of Akt isoforms in IGF-I-mediated signaling and survival in myoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMatheny and Adamo, Biochemical and Biophysical Research Communications 389:117-121 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/art.24225\" rel=\"noopener\" target=\"_blank\"\u003eIncreased expression of the Akt\/PKB inhibitor TRB3 in osteoarthritic chondrocytes inhibits insulin-like growth factor 1-mediated cell survival and proteoglycan synthesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCravero et al., Arthritis \u0026amp; Rheumatism (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2527\/jas.2007-0044\" rel=\"noopener\" target=\"_blank\"\u003eVascularity and expression of angiogenic factors in bovine dominant follicles during the first follicular wave\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGrazul-Bilska et al., Journal of Animal Science (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.bjc.6603435\" rel=\"noopener\" target=\"_blank\"\u003eNFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYang et al., British Journal of Cancer (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.febslet.2006.05.023\" rel=\"noopener\" target=\"_blank\"\u003eHyperosmotic stress activates p65\/RelB NFκB in cultured cardiomyocytes with dichotomic actions on caspase activation and cell death\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eEisner et al., FEBS Letters 580:3469-3476 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpgi.00345.2005\" rel=\"noopener\" target=\"_blank\"\u003eOccupation of alphavbeta3-integrin by endogenous ligands modulates IGF-I receptor activation and proliferation of human intestinal smooth muscle\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKuemmerle, American Journal of Physiology-Gastrointestinal and Liver Physiology 290:G1194-G1202 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1677\/joe.1.06253\" rel=\"noopener\" target=\"_blank\"\u003eEffects of decreased estradiol-17β on the serum and anterior pituitary IGF-I system in pigs\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHilleson-Gayne and Clapper, Journal of Endocrinology (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1530\/eje.1.02028\" rel=\"noopener\" target=\"_blank\"\u003ePro- and mature IGF-II during diet-induced weight loss in obese subjects\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eEspelund et al., European Journal of Endocrinology (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1083\/jcb.200503088\" rel=\"noopener\" target=\"_blank\"\u003eThe p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLuo et al., Journal of Cell Biology (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/MCB.25.7.2593-2606.2005\" rel=\"noopener\" target=\"_blank\"\u003eRole of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBrachmann et al., Molecular and Cellular Biology 25:2593-2606 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2004-1314\" rel=\"noopener\" target=\"_blank\"\u003eTestosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I\/IGFBP-1 concentrations\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVeldhuis et al., Journal of Clinical Endocrinology \u0026amp; Metabolism 90:2941-2947 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpgi.00032.2004\" rel=\"noopener\" target=\"_blank\"\u003eEndogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3β activity\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKuemmerle, American Journal of Physiology-Gastrointestinal and Liver Physiology 288:G101-G110 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/en.2003-1476\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-Like Growth Factor-Induced Transcriptional Activity of the Skeletal α-Actin Gene Is Regulated by Signaling Mechanisms Linked to Voltage-Gated Calcium Channels during Myoblast Differentiation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSpangenburg et al., Endocrinology 145:2054-2063 (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.M311604200\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-like Growth Factor-1 Induces an Inositol 1,4,5-Trisphosphate-dependent Increase in Nuclear and Cytosolic Calcium in Cultured Rat Cardiac Myocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIbarra et al., Journal of Biological Chemistry (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.onc.1207197\" rel=\"noopener\" target=\"_blank\"\u003ePhosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAki et al., Oncogene (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1097\/01.WCB.0000087091.01171.AE\" rel=\"noopener\" target=\"_blank\"\u003eNeuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMackay et al., Journal of Cerebral Blood Flow \u0026amp; Metabolism 23:1160-1167 (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpendo.00410.2002\" rel=\"noopener\" target=\"_blank\"\u003eA highly sensitive and specific assay for determination of IGF-I bioactivity in human serum\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., American Journal of Physiology-Endocrinology and Metabolism 284:E1149-E1155 (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2527\/2002.801214x\" rel=\"noopener\" target=\"_blank\"\u003eAdministration of estradiol-17β increases anterior pituitary IGF-I and relative amounts of serum and anterior pituitary IGF-binding proteins in barrows\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRempel and Clapper, Journal of Animal Science (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpgi.2000.279.5.G975\" rel=\"noopener\" target=\"_blank\"\u003eRegulation of IGFBP-4 levels in human intestinal muscle by an IGF-I-activated, confluence-dependent protease\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKuemmerle and Teng, American Journal of Physiology-Gastrointestinal and Liver Physiology 279:G975-G982 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/jappl.2000.89.4.1365\" rel=\"noopener\" target=\"_blank\"\u003eIGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChakravarthy et al., Journal of Applied Physiology 89:1365-1379 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2527\/2000.78102581x\" rel=\"noopener\" target=\"_blank\"\u003eSerum concentrations of IGF-I, estradiol-17β, testosterone, and relative amounts of IGF-binding proteins in growing boars, barrows, and gilts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eClapper et al., Journal of Animal Science 78:2581-2588 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpendo.2000.279.3.E570\" rel=\"noopener\" target=\"_blank\"\u003eTranscriptional regulation of connective tissue growth factor by cortisol in osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePereira et al., American Journal of Physiology-Endocrinology and Metabolism 279:E570-E576 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1089\/107999000312775\" rel=\"noopener\" target=\"_blank\"\u003eLeptin Expression Is Reduced with Acute Endotoxemia in the Pig: Correlation with Glucose, Insulin, and Insulin-like Growth Factor-1 (IGF-1)\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLeininger et al., Journal of Interferon \u0026amp; Cytokine Research 20:99-106 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.53.37598\" rel=\"noopener\" target=\"_blank\"\u003eProbing the Folding Pathways of Long R3 Insulin-like Growth Factor-I and Insulin-like Growth Factor-I via Disulfide Scrambling\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYang et al., Journal of Biological Chemistry 274:37598-37604 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.140.2.6517\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-Like Growth Factor I Suppresses Parathyroid Hormone\/Parathyroid Hormone-Related Protein Receptor Expression via a Mitogen-Activated Protein Kinase Pathway in UMR-106 Osteoblast-Like Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKawane and Horiuchi, Endocrinology 140:871-879 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI3459\" rel=\"noopener\" target=\"_blank\"\u003eBone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGazzerro et al., Journal of Clinical Investigation 102:2106-2114 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpendo.1998.275.2.E222\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGabbitas and Canalis, American Journal of Physiology-Endocrinology and Metabolism 275:E222-E228 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1096-9861(19980511)394:3%3C386::AID-CNE9%3E3.0.CO;2-Y\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-related growth factors stimulate proliferation of retinal progenitors in the goldfish\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBoucher and Hitchcock, Journal of Comparative Neurology 394:386-394 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.139.4.5950\" rel=\"noopener\" target=\"_blank\"\u003eMitogen-Activated Protein Kinase Kinase Activity Is Required for Inhibition of Skeletal Muscle Differentiation by Insulin-Like Growth Factor 1 or Fibroblast Growth Factor 2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWeyman and Wolfman, Endocrinology 139:1794-1800 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.1998.274.2.C472\" rel=\"noopener\" target=\"_blank\"\u003eEts-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNaito et al., American Journal of Physiology-Cell Physiology 274:C472-C480 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI119663\" rel=\"noopener\" target=\"_blank\"\u003eTargeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Journal of Clinical Investigation 100:1425-1439 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI119081\" rel=\"noopener\" target=\"_blank\"\u003eGenetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHarrela et al., Journal of Clinical Investigation 98:2612-2615 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1042\/BJ3190627\" rel=\"noopener\" target=\"_blank\"\u003eInsulin-like growth factor I and insulin induce adipogenic-related gene expression in fetal brown adipocyte primary cultures\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTeruel et al., Biochemical Journal 319:627-632 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1097-4652(199601)166:1%3C188::AID-JCP20%3E3.0.CO;2-A\" rel=\"noopener\" target=\"_blank\"\u003ePro-inflammatory cytokines downregulate platelet derived growth factor-α receptor gene expression in human osteoblastic cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKöse et al., Journal of Cellular Physiology 166:188-197 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/aacrjournals.org\/cellgrowth\/article\/5\/7\/697\/495745\/\" rel=\"noopener\" target=\"_blank\"\u003ec-erbA and v-erbA modulate growth and gene expression of a mouse glial precursor cell line\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIglesias et al., Cell Growth \u0026amp; Differentiation 5:697-704 (1994).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-050_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52524651446574,"sku":"GF-050-1","price":100.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518874317102,"sku":"GF-050-4","price":80.0,"currency_code":"USD","in_stock":true},{"title":"500 µg","offer_id":52518874349870,"sku":"GF-050-8","price":300.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":52524651479342,"sku":"GF-050-10","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-050-50ug.png?v=1788008668"},{"product_id":"gf-060","title":"Insulin-Like Growth Factor II (IGF-II), Human Recombinant","description":"\u003cp\u003eHuman IGF-II is a potent mitogen for cells of mesodermal origin. It is composed of 67 amino acid residues, and is 62% homologous with human IGF-I. Human IGF-II is produced by genetically engineered yeast, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 7.5 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at -80°C is recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The material is fully active as determined by the receptor-binding assay using a membrane preparation from placenta.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Modern Concepts of Insulin-Like Growth Factor. Ed. E. Martin Spencer, M.D. (1991). Elsevier Science Publ. (New York).\u003cbr\u003e2. Nissley, S. P. and Rechler, M. M. (1984). Insulin-like growth factors: biosynthesis, receptors, and carrier proteins. In C. H. Li (Ed.), Hormonal Proteins and Peptides, Vol. 12, pp. 127-203. Academic Press.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use\"\u003e\n\u003ch3 id=\"ab-published-use-gf-060\"\u003ePublished product use\u003c\/h3\u003e\n\u003cp\u003eA peer-reviewed study reported use of Austral-supplied IGF-II in cell-signaling experiments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCell signaling and adhesion assays:\u003c\/strong\u003e The study reports using IGF-II purchased from Austral Biologics in experiments examining integrin-dependent IGF receptor signaling. \u003ca href=\"https:\/\/doi.org\/10.1083\/jcb.200403003\" rel=\"noopener\" target=\"_blank\"\u003eGoel et al., Journal of Cell Biology (2004)\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-060_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518874382638,"sku":"GF-060-5","price":300.0,"currency_code":"USD","in_stock":true},{"title":"500 µg","offer_id":52518874415406,"sku":"GF-060-8","price":500.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-060-100ug.png?v=1788008657"},{"product_id":"gf-070","title":"Platelet-derived Growth Factor BB (PDGF-BB), Human Recombinant","description":"\u003cp\u003eHuman PDGF-BB homodimer is produced by genetically engineered yeast, and purified by sequential chromatography and ionic exchange HPLC. This polypeptide is composed of two identical polypeptide chains attached by disulfide bonds. As it has been described in the natural product, PDGF-BB is partially clipped at Arg32-Thr33. This cleavage is visible upon reduction of the polypeptide with a reducing agent. Note: this clipping does not affect the biological activity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 97% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C. In solution, at pH 4-7, is stable for 2-3 months at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The material is fully active as determined by its mitogenic activity measured by stimulation of 3H-thymidine incorporation into human foreskin fibroblast cells.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Ross, R. et al. (1986) Cell 46:155\u003cbr\u003e2. Johnson, A. et al. (1984) EMBO J.3:921\u003cbr\u003e3. Waterfield, M.D. et al. (1983) Nature 303: 35\u003cbr\u003e4. Brake, A.J. et al. (1984) Proc. Natl. Acad. Sci. U.S.A. 81(15):4642-4646. doi:10.1073\/pnas.81.15.4642\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-070\"\u003ePublications using Austral Biologicals GF-070\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of PDGF-BB from Austral Biologicals:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/1873-3468.14345\" rel=\"noopener\" target=\"_blank\"\u003eBasic fibroblast growth factor uniquely stimulates quiescent vascular smooth muscle cells and induces proliferation and dedifferentiation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTsuji‐Tamura et al., FEBS Letters 596 1686-1699 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1258\" rel=\"noopener\" target=\"_blank\"\u003eOlaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLowery et al., Clinical Cancer Research 24 847-857 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1167\/iovs.14-13945\" rel=\"noopener\" target=\"_blank\"\u003ePericyte Chemomechanics and the Angiogenic Switch: Insights Into the Pathogenesis of Proliferative Diabetic Retinopathy?\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDurham et al., Investigative Ophthalmology \u0026amp; Visual Science 56(6):3441-3459 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.M113.475285\" rel=\"noopener\" target=\"_blank\"\u003eDissecting the Roles of Tyrosines 490 and 785 of TrkA Protein in the Induction of Downstream Protein Phosphorylation Using Chimeric Receptors\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBiarc et al., Journal of Biological Chemistry 288 16606-16618 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/mcp.M111.013375\" rel=\"noopener\" target=\"_blank\"\u003eThe Induction of Serine\/Threonine Protein Phosphorylations by a PDGFR\/TrkA Chimera in Stably Transfected PC12 Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBiarc et al., Molecular \u0026amp; Cellular Proteomics 11 15-30 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.00536.2009\" rel=\"noopener\" target=\"_blank\"\u003eProtein tyrosine phosphatase PTPεM negatively regulates PDGF β-receptor signaling induced by high glucose and PDGF in vascular smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShimizu et al., American Journal of Physiology-Cell Physiology 299 C1144-C1152 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.00206.2009\" rel=\"noopener\" target=\"_blank\"\u003eROS and PDFG-β receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShimizu et al., American Journal of Physiology-Cell Physiology 297 C389-C396 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1091\/mbc.E05-03-0263\" rel=\"noopener\" target=\"_blank\"\u003eDivergent Roles of c-Src in Controlling Platelet-derived Growth Factor-dependent Signaling in Fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShah et al., Molecular Biology of the Cell 16 5418-5432 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/hep.20719\" rel=\"noopener\" target=\"_blank\"\u003eNAD(P)H oxidase plays a crucial role in PDGF‐induced proliferation of hepatic stellate cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAdachi et al., Hepatology 41 1272-1281 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/hmg\/ddi161\" rel=\"noopener\" target=\"_blank\"\u003eSustained ERK1\/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNowroozi et al., Human Molecular Genetics 14 1529-1538 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/MCB.25.7.2593-2606.2005\" rel=\"noopener\" target=\"_blank\"\u003eRole of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBrachmann et al., Molecular and Cellular Biology 25 2593-2606 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0114\" rel=\"noopener\" target=\"_blank\"\u003eTargeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoizos et al., Molecular Cancer Therapeutics 4 369-379 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1271\/bbb.68.1817\" rel=\"noopener\" target=\"_blank\"\u003eEpigallocatechin-3-O-gallate Inhibits Fibroblast Contraction of Floating Collagen Gel: Interaction between Epigallocatechin-3-O-gallate and Platelet Derived Growth Factor\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSuzuki et al., Bioscience, Biotechnology, and Biochemistry 68 1817-1820 (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3109\/13506120209114099\" rel=\"noopener\" target=\"_blank\"\u003eAcute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKumon et al., Amyloid 9 237-241 (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/ps\/81.8.1191\" rel=\"noopener\" target=\"_blank\"\u003eThe effect of hepatocyte growth factor on turkey satellite cell proliferation and differentiation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZeng et al., Poultry Science 81 1191-1198 (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.bjp.0703771\" rel=\"noopener\" target=\"_blank\"\u003ePlatelet‐derived growth factor causes endothelium‐independent relaxation of rabbit mesenteric artery via the release of a prostanoid\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYamawaki et al., British Journal of Pharmacology 131 1546-1552 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpendo.2000.279.3.E570\" rel=\"noopener\" target=\"_blank\"\u003eTranscriptional regulation of connective tissue growth factor by cortisol in osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePereira et al., American Journal of Physiology-Endocrinology and Metabolism 279 E570-E576 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpheart.1999.277.1.H318\" rel=\"noopener\" target=\"_blank\"\u003eImpairment of EDR by a long-term PDGF treatment in organ-cultured rabbit mesenteric artery\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYamawaki et al., American Journal of Physiology-Heart and Circulatory Physiology 277 H318-H323 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.27.19246\" rel=\"noopener\" target=\"_blank\"\u003eTransient Effect of Platelet-derived Growth Factor on GLUT4 Translocation in 3T3-L1 Adipocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Journal of Biological Chemistry 274 19246-19253 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.96.13.7178\" rel=\"noopener\" target=\"_blank\"\u003eComparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRaffioni et al., Proceedings of the National Academy of Sciences 96 7178-7183 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.10.6783\" rel=\"noopener\" target=\"_blank\"\u003ePlatelet-derived Growth Factor Induces Interleukin-6 Transcription in Osteoblasts through the Activator Protein-1 Complex and Activating Transcription Factor-2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFranchimont et al., Journal of Biological Chemistry 274 6783-6789 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.273.52.35250\" rel=\"noopener\" target=\"_blank\"\u003eEffect of Transmembrane and Kinase Domain Mutations on Fibroblast Growth Factor Receptor 3 Chimera Signaling in PC12 Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRaffioni et al., Journal of Biological Chemistry 273 35250-35259 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.273.52.35161\" rel=\"noopener\" target=\"_blank\"\u003eMolecular Mechanism of Basic Calcium Phosphate Crystal-induced Activation of Human Fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMcCarthy et al., Journal of Biological Chemistry 273 35161-35169 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1177\/00220345980770100601\" rel=\"noopener\" target=\"_blank\"\u003ePDGF-α Receptor Subunit Expression Down-regulated by IL-1β in Human Periodontal Ligament Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOates et al., Journal of Dental Research 77 1791-1798 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.1998.274.2.C472\" rel=\"noopener\" target=\"_blank\"\u003eEts-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNaito et al., American Journal of Physiology-Cell Physiology 274 C472-C480 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/MCB.17.7.4169\" rel=\"noopener\" target=\"_blank\"\u003eChimeras of the Native Form or Achondroplasia Mutant (G375C) of Human Fibroblast Growth Factor Receptor 3 Induce Ligand-Dependent Differentiation of PC12 Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eThompson et al., Molecular and Cellular Biology 17 4169-4177 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1523\/JNEUROSCI.15-11-07095.1995\" rel=\"noopener\" target=\"_blank\"\u003ePDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCheng et al., The Journal of Neuroscience 15 7095-7104 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1042\/bj3100585\" rel=\"noopener\" target=\"_blank\"\u003ePlatelet-derived growth factors-AA and -BB regulate collagen and collagenase gene expression differentially in human fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTan et al., Biochemical Journal 310 585-588 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI117666\" rel=\"noopener\" target=\"_blank\"\u003eFibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFishel et al., Journal of Clinical Investigation 95 377-387 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-070_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874448174,"sku":"GF-070-3","price":80.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518874480942,"sku":"GF-070-5","price":400.0,"currency_code":"USD","in_stock":true},{"title":"500 µg","offer_id":52518874513710,"sku":"GF-070-8","price":1200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-070-10ug.png?v=1788008656"},{"product_id":"gf-080","title":"Platelet derived Growth Factor AA (PDGF-AA), Human Recombinant","description":"\u003cp\u003eHuman PDGF-AA homodimer is produced by genetically engineered yeast, and purified by ionic exchange chromatography and reverse-phase HPLC. This polypeptide is composed of two identical polypeptide chains attached by disulfide bonds.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C. Reconstitution is best in water or buffer near neutral pH.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Thematerial is fully active as measured by the mitogenic assay involving the stimulation of 3H-thymidine incorporation into NIH-3T3 cells.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Heldin, C.H. and Westmark, B. (1990) Celll Regul. 1: 555-566\u003cbr\u003e2. Raines, E. W. et al. (1990) Handbook of Experimental Pharmacology (Sporn, M.B. and Roberts, A.B. eds) Vol 9i5: pages 173-262\u003cbr\u003e3. Ostman, A. et al. (1989) Growth Factors 1: 219-229\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-080\"\u003ePublications using Austral Biologicals GF-080\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of PDGF-AA from Austral Biologicals:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1258\" rel=\"noopener\" target=\"_blank\"\u003eOlaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLowery et al., Clinical Cancer Research 24 847-857 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jim.2013.11.018\" rel=\"noopener\" target=\"_blank\"\u003eIdentification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSchwickart et al., Journal of Immunological Methods 403 52-61 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s10637-012-9912-9\" rel=\"noopener\" target=\"_blank\"\u003eLY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYan et al., Investigational New Drugs 31 833-844 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0114\" rel=\"noopener\" target=\"_blank\"\u003eTargeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoizos et al., Molecular Cancer Therapeutics 4 369-379 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/sj.bjp.0703771\" rel=\"noopener\" target=\"_blank\"\u003ePlatelet‐derived growth factor causes endothelium‐independent relaxation of rabbit mesenteric artery via the release of a prostanoid\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYamawaki et al., British Journal of Pharmacology 131 1546-1552 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1177\/00220345980770100601\" rel=\"noopener\" target=\"_blank\"\u003ePDGF-α Receptor Subunit Expression Down-regulated by IL-1β in Human Periodontal Ligament Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOates et al., Journal of Dental Research 77 1791-1798 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/bjc.1996.496\" rel=\"noopener\" target=\"_blank\"\u003eDifferential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYashiro et al., British Journal of Cancer 74 1096-1103 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/(SICI)1097-4652(199601)166:1%3C188::AID-JCP20%3E3.0.CO;2-A\" rel=\"noopener\" target=\"_blank\"\u003ePro-inflammatory cytokines downregulate platelet derived growth factor-α receptor gene expression in human osteoblastic cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKose et al., Journal of Cellular Physiology 166 188-197 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1523\/JNEUROSCI.15-11-07095.1995\" rel=\"noopener\" target=\"_blank\"\u003ePDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCheng et al., The Journal of Neuroscience 15 7095-7104 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1042\/bj3100585\" rel=\"noopener\" target=\"_blank\"\u003ePlatelet-derived growth factors-AA and -BB regulate collagen and collagenase gene expression differentially in human fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTan et al., Biochemical Journal 310 585-588 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jcp.1041620308\" rel=\"noopener\" target=\"_blank\"\u003eReceptor binding of PDGF‐AA and PDGF‐BB, and the modulation of PDGF receptors by TGF‐β, in human periodontal ligament cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOates et al., Journal of Cellular Physiology 162 359-366 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jbmr.5650100114\" rel=\"noopener\" target=\"_blank\"\u003eInterleukin-1 modulates phosphorylation of proteins in human osteoblastic cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKang et al., Journal of Bone and Mineral Research 10 96-105 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-080_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874546478,"sku":"GF-080-3","price":150.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518874579246,"sku":"GF-080-5","price":850.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-080-10ug.png?v=1788008648"},{"product_id":"gf-090","title":"Tumor Necrosis Factor (TNF alpha), Human Recombinant","description":"\u003cp\u003eHuman Tumor necrosis factor (TNF- alpha), also known as Cachectin, is a cytokine composed of 157 amino acid residues, having a molecular weight of 17 kDa (monomer). There is 79% homology between human and murine TNF- alpha, including conserved cysteine residues which form an intrachain disulfide bridge. Biological effects of this cytokine include antitumor activity in vivo and in vitro, activation of polymorphonuclear leukocytes, antiviral activity, and the induction of the release if Interleukin-1 or colony stimulating factors from a variety of sources. Human TNF- alpha (Cachectin) is produced in genetically engineered yeast, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 17 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The cell cytolytic activity is determined in the L929 cells (3 x 104 cells\/assay) and it is 2-4 x 108 U\/mg.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e At concentration of 1 mg\/mL in 0.02M Tris-HCl\/ 0.15 M NaCl (pH 8.0)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Feinstein, R., Kanety, H., Papa, M.Z., lunenfeld, B., and Karasik, A., (1993) The Journal of Biological Chemistry, Vol 268, No. 35, December, 26055-26058\u003cbr\u003e2. Kalthoff, H., Roeder, C., Brockhaus, M., Thiele, H.G., and Schmiegel, W., (1993) The Journal of Biological Chemistry, Vol 268, No. 4, February, 2762-2766 3. Chaturvedi, M.M. et al. (1994). J. Biol Chem. 269, 14575-14583.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-090_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874612014,"sku":"GF-090-3","price":200.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518874644782,"sku":"GF-090-4","price":600.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-090-10ug.png?v=1788008657"},{"product_id":"gf-230","title":"Transforming Growth Factor Beta-1 (TGF beta-1), Human Recombinant","description":"\u003cp\u003eHuman Transforming Growth Factor beta1 (TGF- beta1 ) is stimulatory for cells of mesenchymal origin and inhibitory for cells of epithelial or neuroectodermal origin. Mature TGF- beta1 is a disulfide-linked homodimer of two chains composed of 112 amino acid residues each. There is a 70% homology between human TGF- beta1 and human TGF- beta2. Human TGF- beta1 is produced in genetically engineered bacteria, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 25 kDa (dimeric protein)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 98% pure by non-reduced SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The biological activity of human TGF-\u0026amp;# beta1 is determined by measuring the acidification of the culture medium (Rat-1 cells) exposed to the growth factor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 25 µL (0.20 mg\/mL) in 5 mM HCl (pH 2.5). Some of the liquid in the vial could have been evaporated with changes in the final volume. However, the 5 µg of the protein are still inside the vial. We recommend, in order to control the proper concentration, to dilute the entire content to a known volume with 5mM HCl. Do not freeze this material.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Ichijo, H. et al.(1994) The Journal of Biological Chemistry, Vol 266, No. 33, May, 22459-22464\u003cbr\u003e2. Yan, Z., Winawer, S., and Friedman, E., (1994) The Journal of Biological Chemistry, Vol 269, No. 18, May, 13231-13237.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-230\"\u003ePublications using GF-230\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3892\/mmr.2017.7607\" rel=\"noopener\" target=\"_blank\"\u003eUpregulation of long noncoding RNA AP003419.16 predicts high risk of aging-associated idiopathic pulmonary fibrosis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHao et al., Molecular Medicine Reports 16 8085-8091 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jcb.25797\" rel=\"noopener\" target=\"_blank\"\u003e7‐Dehydrocholesterol (7‐DHC), But Not Cholesterol, Causes Suppression of Canonical TGF‐β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD)\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Cellular Biochemistry 118 1387-1400 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s12929-016-0229-4\" rel=\"noopener\" target=\"_blank\"\u003eBetulinic acid enhances TGF-β signaling by altering TGF-β receptors partitioning between lipid-raft\/caveolae and non-caveolae membrane microdomains in mink lung epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., Journal of Biomedical Science 23 30 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jcb.25448\" rel=\"noopener\" target=\"_blank\"\u003eDMSO Enhances TGF‐β Activity by Recruiting the Type II TGF‐β Receptor From Intracellular Vesicles to the Plasma Membrane\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Cellular Biochemistry 117 1568-1579 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.bbrc.2016.01.112\" rel=\"noopener\" target=\"_blank\"\u003eTIEG1 enhances Osterix expression and mediates its induction by TGFβ and BMP2 in osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSubramaniam et al., Biochemical and Biophysical Research Communications 470 528-533 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpcell.00262.2014\" rel=\"noopener\" target=\"_blank\"\u003eKrüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePapadakis et al., American Journal of Physiology-Cell Physiology 308 C362-C371 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0038049\" rel=\"noopener\" target=\"_blank\"\u003eClaudin 1 Mediates TNFα-Induced Gene Expression and Cell Migration in Human Lung Carcinoma Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShiozaki et al., PLoS ONE 7 e38049 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0019429\" rel=\"noopener\" target=\"_blank\"\u003eTIEG1\/KLF10 Modulates Runx2 Expression and Activity in Osteoblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHawse et al., PLoS ONE 6 e19429 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/1476-4598-9-122\" rel=\"noopener\" target=\"_blank\"\u003eTargeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGanapathy et al., Molecular Cancer 9 122 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5089\" rel=\"noopener\" target=\"_blank\"\u003eCancer-Associated Transforming Growth Factor β Type II Receptor Gene Mutant Causes Activation of Bone Morphogenic Protein-Smads and Invasive Phenotype\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBharathy et al., Cancer Research 68 1656-1666 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jcp.21303\" rel=\"noopener\" target=\"_blank\"\u003eCholesterol modulates cellular TGF‐β responsiveness by altering TGF‐β binding to TGF‐β receptors\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., Journal of Cellular Physiology 215 223-233 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1242\/jcs.006916\" rel=\"noopener\" target=\"_blank\"\u003eCholesterol suppresses cellular TGF-β responsiveness: implications in atherogenesis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChen et al., Journal of Cell Science 120 3509-3521 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1007\/s10495-007-0085-5\" rel=\"noopener\" target=\"_blank\"\u003ePrevention of TGF-β-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLin et al., Apoptosis 12 1659-1670 (2007).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0162\" rel=\"noopener\" target=\"_blank\"\u003eInhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGe et al., Clinical Cancer Research 12 4315-4330 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17357279\/\" rel=\"noopener\" target=\"_blank\"\u003eTGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSawada et al., Advances in Medical Sciences 51 60-65 (2006).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpgi.00009.2004\" rel=\"noopener\" target=\"_blank\"\u003eIGFBP-3 activates TGF-β receptors and directly inhibits growth in human intestinal smooth muscle cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKuemmerle et al., American Journal of Physiology-Gastrointestinal and Liver Physiology 287 G795-G802 (2004).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1271\/bbb.67.815\" rel=\"noopener\" target=\"_blank\"\u003eDecreased Tumorigenicity In Vivo When Transforming Growth Factor β Treatment Causes Cancer Cell Senescence\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKatakura et al., Bioscience, Biotechnology, and Biochemistry 67 815-821 (2003).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.142.5.8141\" rel=\"noopener\" target=\"_blank\"\u003eAdvanced Glycosylation End Products Up-Regulate Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein-Related Protein 2) in Human Fibroblasts: A Potential Mechanism for Expansion of Extracellular Matrix in Diabetes Mellitus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTwigg et al., Endocrinology 142 1760-1769 (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.M006964200\" rel=\"noopener\" target=\"_blank\"\u003eGrowth Inhibition by Insulin-like Growth Factor-binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-β (TGF-β) and the Type II TGF-β Receptor\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFanayan et al., Journal of Biological Chemistry 275 39146-39151 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1210\/endo.141.9.7684\" rel=\"noopener\" target=\"_blank\"\u003eDifferential Regulation of Insulin-Like Growth Factor-Binding Protein-3 Protease Activity in MCF-7 Breast Cancer Cells by Estrogen and Transforming Growth Factor-β1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSalahifar et al., Endocrinology 141 3104-3110 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1681\/ASN.V113423\" rel=\"noopener\" target=\"_blank\"\u003eExpression of Profilin, an Actin-Binding Protein, in Rat Experimental Glomerulonephritis and Its Upregulation by Basic Fibroblast Growth Factor in Cultured Rat Mesangial Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTamura et al., Journal of the American Society of Nephrology 11 423-433 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.39.27754\" rel=\"noopener\" target=\"_blank\"\u003eAn Active Site of Transforming Growth Factor-β1 for Growth Inhibition and Stimulation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Biological Chemistry 274 27754-27758 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.17.12163\" rel=\"noopener\" target=\"_blank\"\u003eIdentification of Two Smad4 Proteins in Xenopus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMasuyama et al., Journal of Biological Chemistry 274 12163-12170 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.274.10.6711\" rel=\"noopener\" target=\"_blank\"\u003eInteractions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLeal et al., J Biol Chem 274(10):6711-6717 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.273.40.26036\" rel=\"noopener\" target=\"_blank\"\u003eActivated Thyroglobulin Possesses a Transforming Growth Factor-β Activity\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Biological Chemistry 273 26036-26041 (1998).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.272.43.27155\" rel=\"noopener\" target=\"_blank\"\u003eTransforming Growth Factor β Peptide Antagonists and Their Conversion to Partial Agonists\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Biological Chemistry 272 27155-27159 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.272.30.19059\" rel=\"noopener\" target=\"_blank\"\u003eTransforming Growth Factor-β Regulation of Bone Morphogenetic Protein-1\/Procollagen C-proteinase and Related Proteins in Fibrogenic Cells and Keratinocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLee et al., Journal of Biological Chemistry 272 19059-19066 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI119418\" rel=\"noopener\" target=\"_blank\"\u003eOverexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTachibana et al., Journal of Clinical Investigation 99 2365-2374 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1161\/01.RES.78.5.759\" rel=\"noopener\" target=\"_blank\"\u003eSalicylate or Aspirin Inhibits the Induction of the Inducible Nitric Oxide Synthase in Rat Cardiac Fibroblasts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSaeid et al., Circulation Research 78 759-768 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.270.51.30797\" rel=\"noopener\" target=\"_blank\"\u003ePre- and Post-translational Regulation of Lysyl Oxidase by Transforming Growth Factor-β1 in Osteoblastic MC3T3-E1 Cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFeres-Filho et al., Journal of Biological Chemistry 270 30797-30803 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/bjc.1995.434\" rel=\"noopener\" target=\"_blank\"\u003eEffects of transforming growth factor beta-1 on growth-regulatory genes in tumour-derived human oral keratinocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003ePaterson et al., British Journal of Cancer 72 922-927 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-230_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518874677550,"sku":"GF-230-2","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-230-5ug.png?v=1788008647"},{"product_id":"gf-240","title":"Transforming Growth Factor Beta-2 (TGF-Beta 2), Human Recombinant","description":"\u003cp\u003eHuman Transforming Growth Factor beta2 (TGF-beta 2) is stimulatory for cells of mesenchymal origin and inhibitory for cells of epithelial or neuroectodermal origin. Mature TGF- beta2 is a disulfide-linked homodimer of two chains composed of 112 amino acid residues each. There is a 70% homology between human TGF- beta2 and human TGF- beta1. Human TGF- beta2 is produced in genetically engineered e. coli bacteria, and purified by sequential chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 25 kDa (dimeric protein)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 98% pure by non-reduced SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The biological activity of human TGF-\u0026amp;# beta2 is determined by measuring the acidification of the culture medium (Rat-1 cells) exposed to the growth factor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 1 mg\/mL (pH 2.5). CAUTION: Since the volume supplied is small, we advise our customers to dilute this material to a working stock solution. To remove partial aliquots in not recommended.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Moustakas, A., Lin, H.Y., Henis, Y.I., Plamondon, J., O'Conner-McCourt, M.D., and Lodish, H.F., (1993) The Journal of Biological Chemistry, Vol 268, 30, October, 22215-22218.\u003cbr\u003e2. Geiser, A.G., Burmester, J.K., Webbink, R., Roberts, A.B., and Sporn, M.B., (1992). The Journal of Biological Chemistry, Vol 267, 4, February, 2588-2593.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-gf-240\"\u003ePublications using Austral Biologicals GF-240\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of TGF-β2 from Austral Biologicals:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2476\" rel=\"noopener\" target=\"_blank\"\u003eTrastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMimura et al., Clinical Cancer Research 11(13):4898-4904 (2005).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/S0002-9440(10)64803-1\" rel=\"noopener\" target=\"_blank\"\u003eKeloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChodon et al., American Journal of Pathology 157(5):1661-1669 (2000).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.2176\/nmc.36.789\" rel=\"noopener\" target=\"_blank\"\u003eTransforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNaganuma et al., Neurologia Medico-Chirurgica 36(11):789-795 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1136\/ard.55.3.181\" rel=\"noopener\" target=\"_blank\"\u003eEffects of transforming growth factor betas and basic fibroblast growth factor on articular chondrocytes obtained from immobilised rabbit knees\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eOkazaki et al., Annals of the Rheumatic Diseases 55(3):181-186 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1136\/bjo.80.1.63\" rel=\"noopener\" target=\"_blank\"\u003eEffects of the cytokines on the proliferation of and collagen synthesis by human cataract lens epithelial cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNishi et al., British Journal of Ophthalmology 80(1):63-68 (1996).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1002\/jcp.1041650215\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of transforming growth factor-beta growth regulatory effects and receptors on bovine mammary cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWoodward et al., Journal of Cellular Physiology 165(2):339-348 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1136\/bjo.79.10.934\" rel=\"noopener\" target=\"_blank\"\u003eEffect of the cytokines on the prostaglandin E2 synthesis by lens epithelial cells of human cataracts\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNishi et al., British Journal of Ophthalmology 79(10):934-938 (1995).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1091\/mbc.3.11.1295\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMitchell et al., Molecular Biology of the Cell 3(11):1295-1307 (1992).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-240_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"5 µg","offer_id":52518874710318,"sku":"GF-240-2","price":250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-240-5ug.png?v=1788008646"},{"product_id":"gf-390","title":"Macrophage Colony Stimulator Factor (M-CSF), Human Recombinant","description":"\u003cp\u003eHuman M-CSF is produced in genetically engineered E. coli cells, and purified by sequential chromatography, refolding and HPLC. This polypeptide is a disulfide-linked dimeric protein (1).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 55 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 92% pure by amino acid composition and SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at -20°C. It is less stable in a solution of a pH lower than 5.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The biological activity of human M-CSF is measured by the mouse bone marrow colony-forming assay (2). The specific activity is 6 X 107 U\/mg.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e M-CSF is at 1 mg\/mL in 0.1% Mannitol, 0.1M Citrate (pH 6.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Halenbeck, R. et al. (1989) Biotechnology 7: 710-714\u003cbr\u003e2. Kawasaki, E.S. et al. (1985) Science 230: 291:296\u003cbr\u003e3. Suzu, S. et al. (1989) Cancer Res. 49:5913-5917\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use\"\u003e\n\u003ch3 id=\"ab-published-use-gf-390\"\u003ePublished product use\u003c\/h3\u003e\n\u003cp\u003eA peer-reviewed study reported in-vivo use of recombinant human M-CSF from Austral Biologicals:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIn-vivo cytokine treatment:\u003c\/strong\u003e Recombinant human M-CSF from Austral Biologicals was administered intraperitoneally at 5 µg per mouse in the reported osteoclast-recruitment experiments. \u003ca href=\"https:\/\/doi.org\/10.1084\/jem.190.2.293\" rel=\"noopener\" target=\"_blank\"\u003eNiida et al., Journal of Experimental Medicine (1999)\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-390_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874775854,"sku":"GF-390-3","price":200.0,"currency_code":"USD","in_stock":true},{"title":"50 µg","offer_id":52518874808622,"sku":"GF-390-4","price":700.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-390-10ug.png?v=1788008664"},{"product_id":"gf-810","title":"Superoxide Dismutase (SOD), Human Recombinant","description":"\u003cp\u003eCu\/Zn Human Superoxide Dismutase is a stable dimer of identical subunits with a combined molecular mass of 32,000 daltons. This enzyme dismutes the superoxide radical to molecular oxygen. This enzyme has been expressed in yeast and purified using sequential chromatography steps. The hSOD is acetylated at its N-terminus. Human SOD is produced in genetically engineered yeast, and purified by ionic exchange chromatography.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 32 kDa (dimeric protein)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 98% pure by non-reduced SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Several months at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The specific activity of SOD is 260 U\/mg. The enzymatic activity of human SOD is determined by calorimetrically determining the oxidation of a chromophore. This was performed with a commercially available kit called SOD-525 from Bioxytech S.A. (Cedex, France).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 10 mg\/mL in water (no additive is added)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. R. A. Hallewel et al, J. Biol. Chem. (1989), 264, 5260-5268.\u003cbr\u003e2. R.A. Hallewell et al (1987), Biotechnology 5, 363-366.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GF-810_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"20 µg","offer_id":52524461654318,"sku":"GF-810-1","price":50.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52524461687086,"sku":"GF-810-3","price":120.0,"currency_code":"USD","in_stock":true},{"title":"500 µg","offer_id":52518874841390,"sku":"GF-810-8","price":200.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":52517541904686,"sku":"GF-810-9","price":350.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gf-810-500ug.png?v=1788008646"},{"product_id":"gr-020","title":"Human NGF receptor extracellular domain (RECOMBINANT)","description":"\u003cp\u003eHuman NGF receptor extracellular domain is produced by genetically engineered Chinese hamster ovary cells (CHO cells) and purified by lectin affinity chromatography.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 42.5 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 85% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 2 months at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The human NGF receptor extracellular domain is able to bind NGF.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 20 mM HEPES, pH 7.3.\/ 0.1M NaCl. Concentration: 1.0 mg protein\/ml.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Kahle, P., and Hertel, C. (1991).\u003cbr\u003e2. The Journal of Biological Chemistry, Vol 267, No. 20, 13917-13923.\u003cbr\u003e3. Rabizadeh, S., Oh, J., Zhong, L., Yang, J., Bitler, C.M., Butcher, L. and Bredesen, D.E. (1993) Science, Vol 261, 245-248. 3. Baldwin, A.N., and Shooter, E.M. (1994) The Journal of Biological Chemistry, Vol 269, No. 15, 11456-11461.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GR-020_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518874874158,"sku":"GR-020-3","price":100.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518874906926,"sku":"GR-020-5","price":900.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gr-020-10ug.png?v=1788008657"},{"product_id":"gr-080","title":"Human PDGF alpha-receptor extracellular domain (RECOMBINANT)","description":"\u003cp\u003eHuman PDGF alpha receptor extracellular domain is produced by genetically engineered Spodoptera frugiperda insect cells (Sf9) infected with recombinant baculovirus, and purified by lectin affinity chromatography.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 85% pure by SDS gel electrophoresis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 2 months at -80°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e The material is able to bind the ligand (PDGF) as demonstrated by immobilizing the PDGF receptor extracellular domain and establishing competition of binding with radioiodinated PDGF.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e 10 mM Tris-HCl, pH 7.0. Concentration: 0.50 mg protein\/ml.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Gronwald, R.et al (1988) Proc Natl Acad Sci U S A 85, 3435-39.\u003cbr\u003e2. Hart, C. E.et al (1988) Science 240, 1529-31.\u003cbr\u003e3 Tiesman, J., and Hart, C. E. (1993) J Biol Chem 268, 9621-8.\u003cbr\u003e4. Kelly, J. D.et al. (1991) J Biol Chem 266, 8987-92.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_GR-080_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"10 µg","offer_id":52518875005230,"sku":"GR-080-3","price":200.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518875037998,"sku":"GR-080-5","price":1500.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-gr-080-10ug.png?v=1788008646"},{"product_id":"ma-011","title":"Anti-human EGF IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-human EGF IgG fraction is a monoclonal antibody raised against purified human recombinant EGF expressed in yeast cells. The antigen was purified by sequential chromatography (Final: reverse-phase HPLC). The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant EGF in the oxidized or reduced form of the protein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.50 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-011_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879953198,"sku":"MA-011-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-011-100ug.png?v=1788008380"},{"product_id":"ma-022","title":"Anti-bovine NGF IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-bovine nerve growth factor IgG fraction is a monoclonal antibody raised against purified bovine NGF. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes bovine NGF by Western analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.25 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-022_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879985966,"sku":"MA-022-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-022-100ug.png?v=1788008357"},{"product_id":"ma-031","title":"Anti-human FGF2 (basic) IgG fraction (monoclonal) (clone 1H5\/I)","description":"\u003cp\u003eMouse monoclonal antibody IgG fraction (clone 1H5\/I) obtained by immunizing mice with a purified human recombinant basic FGF expressed in yeast cells. The antigen was purified by sequential chromatography. The IgG fraction was purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA (1: 8,000 dilution) and Western blot (1:10,000 dilution) assays. It recognizes human recombinant basic FGF and does not cross react with human recombinant acidic FGF.\nStorage: Keep frozen at -20°C. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 1 mg\/mL in PBS (pH 7.4). Some of the liquid in the vial could have been evaporated with changes in the final volume. However, the mass of the protein is still inside the vial.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-031_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880018734,"sku":"MA-031-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-031-100ug.png?v=1788008359"},{"product_id":"ma-031b","title":"Anti-human FGF2 (basic) IgG fraction (monoclonal) (clone 6B3\/I5)","description":"\u003cp\u003eMouse monoclonal antibody IgG fraction (clone 6B3\/I5) obtained by immunizing mice with a purified human recombinant basic FGF expressed in yeast cells. The antigen was purified by sequential chromatography. The IgG fraction was purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA (1: 8,000 dilution) and Western blot (1:10,000 dilution) assays. It recognizes human recombinant basic FGF and does not cross react with human recombinant acidic FGF.\nStorage: Keep frozen at -20°C. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 1 mg\/mL in PBS (pH 7.4). Some of the liquid in the vial could have been evaporated with changes in the final volume. However, the mass of the protein is still inside the vial.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-031B_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880051502,"sku":"MA-031B-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-031b-100ug.png?v=1788008380"},{"product_id":"ma-041","title":"Anti-human acidic FGF IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-human acidic FGF IgG fraction is a monoclonal antibody raised against purified human recombinant acidic FGF expressed in yeast cells. The antigen was purified by sequential chromatography. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant acidic FGF by Western analysis and ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.50 mg\/mL. Formulated in PBS (pH 7.2)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-041_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880084270,"sku":"MA-041-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-041-100ug.png?v=1788008391"},{"product_id":"ma-051","title":"Anti-Human IGF-I, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human IGF-I IgG fraction is a monoclonal antibody raised against purified human recombinant IGF-I expressed in yeast cells. The antigen was purified by sequential chromatography. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Using a 1:100 dilution, together with the alkaline phosphatase detection system, this antibody reacts positively by Western blot to both IGF-I and IGF-II. This monoclonal antibody also recognizes recombinant IGF-I by ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.25 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-ma-051\"\u003ePublications using Austral Biologicals MA-051\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use the anti-human IGF-I monoclonal antibody from Austral Biologicals:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1083\/jcb.144.5.1069\" rel=\"noopener\" target=\"_blank\"\u003eType IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eZhu et al., Journal of Cell Biology 144(5):1069-1080 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1152\/ajprenal.1997.273.6.F899\" rel=\"noopener\" target=\"_blank\"\u003eHeparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eAbrass et al., American Journal of Physiology-Renal Physiology 273(6):F899-F906 (1997).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-051_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880117038,"sku":"MA-051-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-051-100ug.png?v=1788008359"},{"product_id":"ma-061","title":"Anti-human IGF-II IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-human IGF-II IgG fraction is a monoclonal antibody raised against purified human recombinant IGF-II expressed in yeast cells. The antigen was purified by sequential chromatography. The monoclonal antibody is purified using Protein G. IgG Subtype: IgG-2a.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant IGF-II by Western analysis and ELISA. This monoclonal antibody cross-reacts slightly with IGF-I when used in a 1\/100 dilution on a Western assay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.50 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-061_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880149806,"sku":"MA-061-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-061-100ug.png?v=1788008357"},{"product_id":"ma-071","title":"Anti-human PDGF-BB IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-human PDGF-BB IgG fraction is a monoclonal antibody raised against purified human recombinant PDGF-BB. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This purified monoclonal antibody recognizes recombinant human PDGF-BB in the oxidized or reduced form by Western blot analysis using a 1:100 dilution together with the alkaline phosphatase detection sysytem.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.50 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-071_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880182574,"sku":"MA-071-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-071-100ug.png?v=1788008376"},{"product_id":"ma-081","title":"Anti-Human PDGF-AA, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human PDGF-AA IgG fraction is a monoclonal antibody raised against purified human recombinant PDGF-AA. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant PDGF-AA with variable intensity depending upon the reduced state of the polypeptide as evidenced by Western analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.25 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-081_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880215342,"sku":"MA-081-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-081-100ug.png?v=1788008380"},{"product_id":"ma-091","title":"Anti-Human TNF Alpha, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human TNF alpha IgG fraction is a monoclonal antibody raised against purified human recombinant TNF (Cat GF-090) expressed in yeast cells. The antigen was purified by sequential chromatography. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant TNF alpha in a Western analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid at 0.25 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-ma-091\"\u003ePublications using MA-091\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/j.1349-7006.1999.tb00827.x\" rel=\"noopener\" target=\"_blank\"\u003eExpression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eNakano et al., Jpn J Cancer Res 90(8):858-866 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-091_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880248110,"sku":"MA-091-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-091-100ug.png?v=1788008357"},{"product_id":"ma-1001","title":"Anti-Tissue Factor Pathway Inhibitor (TFPI) . IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 8E4\/E9) obtained by immunization of mice with an N-terminal region of TFPI (aa1 – aa160). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay (1:2,000 dilution). TFPI is the main physiological inhibitor of the extrinsic coagulation pathway. It is a Kunitz-type serine protease inhibitor comprising three tandem units, the first and second units inhibit Factor VIIa\/tissue factor complex and factor Xa respectively.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Price, G.C. et al. (2004) Anaesthesia 59, 483 - 492.\u003cbr\u003eJohnson, K. et al. (1998) Thromb. Haemost. 80, 585 - 587.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-1001_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880280878,"sku":"MA-1001-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-1001-100ug.png?v=1788008357"},{"product_id":"ma-1011a","title":"Anti-Tissue Factor Pathway Inhibitor (TFPI). IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 6F3\/C12) obtained by immunization of mice with a truncated TFPI (34 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay (1:2,000 dilution). TFPI is the main physiological inhibitor of the extrinsic coagulation pathway. It is a Kunitz-type serine protease inhibitor comprising three tandem units; the first and second units inhibit Factor VIIa\/tissue factor complex and factor Xa respectively.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Price, G.C. et al. (2004) Anaesthesia 59, 483 - 492.\u003cbr\u003eJohnson, K. et al. (1998) Thromb. Haemost. 80, 585 - 587.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-1011A_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880313646,"sku":"MA-1011a-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-1011a-100ug.png?v=1788008335"},{"product_id":"ma-1011b","title":"Anti-Tissue Factor Pathway Inhibitor TFPI (34 kDa). IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 4B6\/D8) obtained by immunization of mice with a truncated TFPI (34 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay (1:2,000 dilution). TFPI is the main physiological inhibitor of the extrinsic coagulation pathway. It is a Kunitz-type serine protease inhibitor comprising three tandem units; the first and second units inhibit Factor VIIa\/tissue factor complex and factor Xa respectively.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Price, G.C. et al. (2004) Anaesthesia 59, 483 - 492.\u003cbr\u003eJohnson, K. et al. (1998) Thromb. Haemost. 80, 585 - 587.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-1011B_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880346414,"sku":"MA-1011b-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-1011b-100ug.png?v=1788008325"},{"product_id":"ma-1301","title":"Anti-human Complement Activation Blocker-2 (CAB-2). IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 4E5\/C6) obtained by immunization of mice with human complement activation protein blocker-2, CAB-2 (110 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay (1:2,000 dilution). CAB-2 is a soluble chimeric protein derived from human decay accelerating factor (CD55) and membrane cofactor protein (CD46). It inhibits C3 and C5 convertases of both classical and alternative pathway. It also blocks the activation of complement in vivo.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Higgins, P.J. et al. (1997) J. Immunol. 158, 2872 - 2881\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-1301_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880379182,"sku":"MA-1301-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-1301-100ug.png?v=1788008336"},{"product_id":"ma-291","title":"Anti-Human MIP-1 alpha, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human MIP-1 alpha IgG fraction is a monoclonal antibody raised against purified human recombinant MIP-1 alpha is produced in genetically engineered yeast, and purified by sequential chromatography. It is purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Using a working concentration of 17 µg antibody\/ml, together with the alkaline phosphatase detection system, this antibody reacts with rh-MIP-1 alpha and with rh-MIP-1 beta. There is no detection, by Western blot, of rh-MIP-2 alpha or rh-MIP-2 beta. This monoclonal antibody also recognizes recombinant human MIP-1 alpha by ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. 100 µg. Frozen liquid. 0.25 mg\/mL formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-291_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880411950,"sku":"MA-291-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-291-100ug.png?v=1788008342"},{"product_id":"ma-301","title":"Anti-Human MIP-1 beta, IgG Fraction,  Monoclonal","description":"\u003cp\u003eAnti-human MIP-1 beta IgG fraction is a monoclonal antibody raised against purified human recombinant MIP-1 beta. The antigen was produced in genetically engineered yeast, and purified by sequential chromatography. The monoclonal antibody was purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant human MIP-1 beta by Western analysis (1\/100 dilution) and ELISA. This antibody is very specific for MIP-1 beta, presenting no cross reactivity with other MIPs proteins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. 100 µg. Frozen liquid. 0.50 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Wolpe, S.D. et al (1989) The FASEB Journal, 3, 2565-2573.\u003cbr\u003e2. Sherry, B et al (1988) J. Exp. Med. 168, 2251-2259.\u003cbr\u003e3. Wolpe, S.D. et al (1988) J. Exp. Med. 167, 570-581.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880444718,"sku":"MA-301-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-301-100ug.png?v=1788008347"},{"product_id":"ma-311","title":"Anti-Human MIP-2 alpha, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human MIP-2 alpha IgG fraction is a monoclonal antibody raised against purified human recombinant MIP-2 alpha is produced in genetically engineered yeast, and purified by sequential chromatography. It is purified using Protein G. IgG Subtype: IgG-2b\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant human MIP-2 alpha by Western analysis using a concentration of 10 µg\/ml together with the alkaline phosphatase detection system. Under these conditions, this antibody cross reacts with rh-MIP-2 beta and does not crossreact with rh-MIP-1 alpha or rh-MIP-1 beta. This antibody also recognizes rh-MIP-2 alpha ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. 100 µg. Frozen liquid. 0.25 mg\/mL Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880477486,"sku":"MA-311-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-311-100ug.png?v=1788008335"},{"product_id":"ma-321","title":"Anti-Human MIP-2 beta, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human MIP-2 beta IgG fraction (IgGl) is a monoclonal antibody raised against purified human recombinant MIP-2 beta. The antigen was produced in genetically engineered yeast, and purified by sequential chromatography. The monoclonal antibody was purified using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes recombinant human MIP-2 beta by Western analysis (1\/100 dilution) and ELISA. This antibody is very specific for MIP-2 beta, presenting a slight cross reactivity with MIP-2 alpha, but no other MIP proteins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG (IgG1) fraction. 100 µg (500 µL). Frozen liquid. 0.20 mg\/mL Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Wolpe, S.D. et al (1989) The FASEB Journal, 3, 2565-2573.\u003cbr\u003e2. Sherry, B et al (1988) J. Exp. Med. 168, 2251-2259.\u003cbr\u003e3. Wolpe, S.D. et al (1988) J. Exp. Med. 167, 570-581.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880510254,"sku":"MA-321-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-321-100ug.png?v=1788008325"},{"product_id":"ma-331","title":"Anti-mouse EGF IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-mouse EGF IgG fraction is a monoclonal antibody raised against purified recombinant mouse EGF expressed in yeast cells, and purified by sequential chromatography (Final: reverse-phase HPLC). The monoclonal antibody is purified using Protein G. IgG Subtype: IgG-1.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes mouse recombinant EGF in the oxidized or reduced form of the protein. It does not cross react with human EGF on a Western blot assay (1\/100 dilution)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.50 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-331_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880543022,"sku":"MA-331-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-331-100ug.png?v=1788008358"},{"product_id":"ma-341","title":"Anti-human NGF IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-humane nerve growth factor IgG fraction is a monoclonal antibody raised against purified NGF. The monoclonal antibody is purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes human NGF.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 0.25 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-341_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880575790,"sku":"MA-341-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-341-100ug.png?v=1788008320"},{"product_id":"ma-351","title":"Anti-human IGF-Binding protein 2 IgG fraction (monoclonal)","description":"\u003cp\u003eAnti-human IGF-Binding protein 2 IgG (IgM) fraction is a monoclonal antibody produced in mouse and elicited to human recombinant IGF-binding Protein 2 (yeast derived recombinant protein). It is purified by affinity chromatography using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes human IGFBP-2 on ELISA analysis. This antibody can be used for Western blot analysis, however it is only immunoreactive under reduced conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG (IgM) fraction. Frozen liquid. 0.1 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-351_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880608558,"sku":"MA-351-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-351-100ug.png?v=1788008348"},{"product_id":"ma-361","title":"Anti-Human IGF-Binding Protein 4, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human IGF-Binding protein 4 IgG (IgG-1) fraction is a monoclonal antibody produced in mouse and elicited to human recombinant IGF-binding Protein 4 (yeast derived recombinant protein). It is purified by affinity chromatography using Protein G. The respective epitope, on IGF-BP4, recognized by this antibody has not yet been determined.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody strongly recognizes human IGFBP-4 on ELISA or Western blot analysis. It does not present cross-reactivity to other IGF-BPs on a Western blot analysis (1\/100 dilution)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 100 µg at 0.1 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-ma-361\"\u003ePublications using MA-361\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publication report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1530\/rep.0.1220865\" rel=\"noopener\" target=\"_blank\"\u003eEffect of nitric oxide on the expression of insulin-like growth factors and the insulin-like growth factor binding proteins throughout the lifespan of the human corpus luteum\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIñiguez et al., Reproduction 122(6):865-873 (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-361_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880641326,"sku":"MA-361-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-361-100ug.png?v=1788008323"},{"product_id":"ma-371","title":"Anti-human IGF-Binding Protein 5, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human IGF-Binding protein 5 IgG (IgG-1) fraction is a monoclonal antibody produced in mouse and elicited to human recombinant IGF-binding Protein 5 (yeast derived recombinant protein). It is purified by affinity chromatography using Protein G. The respective epitope, on IGF-BP5, recognized by this antibody has not yet been determined.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody strongly recognizes human IGFBP-5 on ELISA or Western blot analysis. It does not present cross-reactivity to other IGF-BPs on a Western blot analysis (1\/100 dilution)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction (IgG-1) in liquid. 100 µg at 1 mg\/mL. Formulated in PBS (pH 7.4). Some of the liquid in the vial could have evaporated with changes in the final volume. However, the mass of the protein is still inside the vial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-ma-371\"\u003ePublications using MA-371\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.fertnstert.2008.12.096\" rel=\"noopener\" target=\"_blank\"\u003eExpression of the IGF and insulin systems in the luteinizing macaque ovarian follicle\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBrogan et al., Fertil Steril 93(5):1421-1429 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1530\/rep.0.1220865\" rel=\"noopener\" target=\"_blank\"\u003eEffect of nitric oxide on the expression of insulin-like growth factors and the insulin-like growth factor binding proteins throughout the lifespan of the human corpus luteum\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIñiguez et al., Reproduction 122(6):865-873 (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880674094,"sku":"MA-371-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-371-100ug.png?v=1788008325"},{"product_id":"ma-381","title":"Anti-Human IGF-Binding Protein 6, IgG Fraction, Monoclonal","description":"\u003cp\u003eAnti-human IGF-Binding protein 6 IgG fraction is a monoclonal antibody produced in mouse and elicited to human recombinant IGF-binding Protein 6 (yeast derived recombinant protein). It is purified by affinity chromatography using Protein G.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This monoclonal antibody recognizes human IGFBP-6 on ELISA analysis. This antibody is not recomended for Western blot analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e IgG fraction. Frozen liquid. 100 µg at 0.1 mg\/mL. Formulated in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-ma-381\"\u003ePublications using MA-381\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of this Austral Biologicals product:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1530\/rep.0.1220865\" rel=\"noopener\" target=\"_blank\"\u003eEffect of nitric oxide on the expression of insulin-like growth factors and the insulin-like growth factor binding proteins throughout the lifespan of the human corpus luteum\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIñiguez et al., Reproduction 122(6):865-873 (2001).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1677\/joe.0.1600305\" rel=\"noopener\" target=\"_blank\"\u003eCellular distribution and ontogeny of insulin-like growth factors (IGFs) and IGF binding protein messenger RNAs and peptides in developing rat pancreas\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHill et al., J Endocrinol 160(2):305-317 (1999).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-381_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880706862,"sku":"MA-381-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-381-100ug.png?v=1788008334"},{"product_id":"ma-4001","title":"Anti-human Integrin Beta 1 (CD29). IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 2A2\/I6) obtained by immunization of mice with human HeLa cells. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay. Integrins are a family of divalent-cation dependent cell adhesion receptors that express a conserved ß chain (ß1 or CD29, and ß2 or CD13) associated non-covalently with different a chains. Integrin ß1 mediates the leukocyte adhesion to extra-cellular matrix proteins and endothelium to regulate the efficiency and specificity of trafficking into secondary lymphoid organs and peripheral tissue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Pribila, J.T. et al. (2004) Ann. Rev. Immunol. 22, 157 - 180.\u003cbr\u003eBalzac, F. et al. (1993) J. Cell Biol. 121, 171 - 178.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-4001_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"200 µg","offer_id":52518880739630,"sku":"MA-4001-6","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-4001-200ug.png?v=1788008323"},{"product_id":"ma-4011","title":"Anti-human Vascular Cell Adhesion Protein 1(VCAM-1 or CD106). IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 6G10\/8) obtained by immunization of mice with human umbilical vein endothelial cells (HUVEC) activated with a TNF. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for functional studies of cell adhesion molecules. VCAM-1 is the receptor for ß-1 integrin VL4 on leukocytes and mediates both adhesion and signal transduction. The VCAM1-VL4 interaction may play a patho-physiologic role both in immune responses and in leukocyte emigration to sites of inflammation. This interaction is important in the specific tumor destruction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Jin, Z. et al. (2004) Int. J. Cancer 111, 558 - 567.\u003cbr\u003eHession, C. et al. (1991) J. Biol. Chem. 266, 6682 - 6685.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-4011_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"200 µg","offer_id":52518880772398,"sku":"MA-4011-6","price":275.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-4011-200ug.png?v=1788008347"},{"product_id":"ma-4021","title":"Anti-mouse Cathepsin S. IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 4B3\/A8) obtained by immunization of mice with Cathepsin S. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used for ELISA assay. Cathepsin S is a cysteine proteinase that is reported to be involved in antigen presentation and may play a role in tumor progression.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Lennon-Duménil, A.M. et al. (2002) J. Exp. Med. 196, 529 - 539.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-4021_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880805166,"sku":"MA-4021-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-4021-100ug.png?v=1788008354"},{"product_id":"ma-4031","title":"Anti-human Class II Transactivator (Ciita) IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 7D3\/A1) obtained by immunization of mice with recombinant human CIITA fusion protein. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA, Western Blot, and immunoprecipitation. It recognizes CIITA, a non-DNA binding coactivator considered as the master regulator of basal and induced MHC class II specific gene expression. CIITA ensures a tight transcriptional control of these antigen-presenting genes to meet with local requirements for an adequate immune response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e LeibundGut-Landmann, S. et al. (2004) Eur. J. Immunol. 34, 1513 – 1525; Van den Elsen, P. et al. (2004) Curr. Opin. Immunol. 16, 67 – 75 ; Naves, R. et al. (2002) Int. Immunol. 14, 481 – 491.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_MA-4031_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518880837934,"sku":"MA-4031-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-ma-4031-100ug.png?v=1788008346"}],"url":"https:\/\/www.australbiologicals.com\/collections\/growth-factors-and-cytokines.oembed","provider":"Austral Biologicals","version":"1.0","type":"link"}